

# CITATION REPORT

List of articles citing

## A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19

DOI: 10.1056/nejmoa2016638

New England Journal of Medicine, 2020, 383, 517-525.

**Source:** <https://exaly.com/paper-pdf/76672062/citation-report.pdf>

**Version:** 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
985	Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study. <b>2020</b> , 202, 1656-1665		72
984	Antifibrotics in COVID-19 Lung Disease: Let Us Stay Focused. <b>2020</b> , 7, 539		12
983	Recent findings on the Coronavirus disease 2019 (COVID-19); immunopathogenesis and immunotherapeutics. <b>2020</b> , 89, 107082		10
982	Time to Treat: Applying Lessons Learned from Other Viral Syndromes to SARS-CoV-2. <b>2020</b> , 4, 759-763		3
981	Nebulized ivermectin for COVID-19 and other respiratory diseases, a proof of concept, dose-ranging study in rats. <b>2020</b> , 10, 17073		16
980	Clinical management of Lupus patients during the COVID-19 pandemic. <b>2020</b> , 29, 1661-1672		7
979	Health Diplomacy in Pandemical Times. <b>2020</b> , 74, E78-E97		38
978	Severe COVID-19: what have we learned with the immunopathogenesis?. <b>2020</b> , 60, 50		29
977	Oxidative Stress, Proton Fluxes, and Chloroquine/Hydroxychloroquine Treatment for COVID-19. <b>2020</b> , 9,		9
976	Malaria and COVID-19: Common and Different Findings. <b>2020</b> , 5,		31
975	"Compliance of the Indian National Task Force guidelines for COVID-19 recommendation by Indian doctors - A survey". <b>2020</b> , 14, 1413-1418		2
974	Leveraging the advances in HIV for COVID-19. <b>2020</b> , 396, 943-944		3
973	The Exclusion of Older Persons From Vaccine and Treatment Trials for Coronavirus Disease 2019-Missing the Target. <b>2020</b> , 180, 1546-1549		37
972	A review of medications used to control and improve the signs and symptoms of COVID-19 patients. <b>2020</b> , 887, 173568		2
971	Claims about the safety and efficacy of early treatment of COVID-19 with hydroxychloroquine and azithromycin must be supported by real evidence. <b>2020</b> , 38, 101886		
970	Analysis of the US FDA adverse event reporting system to identify adverse cardiac events associated with hydroxychloroquine in older adults. <b>2020</b> , 29, 1689-1695		1
969	Assessment of Chloroquine and Hydroxychloroquine Safety Profiles: A Systematic Review and Meta-Analysis. <b>2020</b> , 11, 562777		7

968	Dual-histamine receptor blockade with cetirizine - famotidine reduces pulmonary symptoms in COVID-19 patients. <b>2020</b> , 63, 101942	39
967	Pragmatic, adaptive clinical trials: Is 2020 the dawning of a new age?. <b>2020</b> , 19, 100614	6
966	Antiviral monotherapy for hospitalised patients with COVID-19 is not enough. <b>2020</b> , 396, 1310-1311	10
965	[Treatment of Sars-Cov2 with hydroxychloroquine is ineffective and potentially harmful]. <b>2020</b> , 2020, 25-27	0
964	COVID-19 disparities: An urgent call for race reporting and representation in clinical research. <b>2020</b> , 19, 100630	24
963	Hydroxychloroquine in Hospitalized Patients with COVID-19: Real-World Experience Assessing Mortality. <b>2020</b> , 40, 1072-1081	9
962	Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity. <b>2020</b> , 117, 26955-26965	138
961	Novel corona virus (COVID-19) pandemic: current status and possible strategies for detection and treatment of the disease. <b>2020</b> , 1-24	11
960	Virtual and Antiviral Screening Revive Therapeutic Drugs for COVID-19. <b>2020</b> , 3, 1278-1292	22
959	Evidence-based management of COVID-19 in cancer patients: Guideline by the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). <b>2020</b> , 140, 86-104	14
958	Chloroquine to fight COVID-19: A consideration of mechanisms and adverse effects?. <b>2020</b> , 6, e04900	9
957	Diagnostic technologies for COVID-19: a review.. <b>2020</b> , 10, 35257-35264	14
956	Pandemic and promise: progress towards finding an effective treatment for Novel Coronavirus 19. <b>2020</b> , 44, 437-439	0
955	Use of hydroxychloroquine and chloroquine in COVID-19: How good is the quality of randomized controlled trials?. <b>2020</b> , 101, 107-120	5
954	Do free radical Network and oxidative stress disparities in African Americans enhance their vulnerability to SARS-CoV-2 infection and COVID-19 severity?. <b>2020</b> , 37, 101721	11
953	The immuno-oncological challenge of COVID-19.. <b>2020</b> , 1, 946-964	52
952	Combining hydroxychloroquine and minocycline: potential role in moderate to severe COVID-19 infection. <b>2020</b> , 13, 1183-1190	5
951	In the Fog of COVID. <b>2020</b> ,	

950	Pharmaco-Immunomodulatory Therapy in COVID-19. <b>2020</b> , 80, 1267-1292	128
949	Recent Advancements in the Diagnosis, Prevention, and Prospective Drug Therapy of COVID-19. <b>2020</b> , 8, 384	7
948	"Warp Speed" Operations in the COVID-19 Pandemic: Moving Too Quickly?. <b>2020</b> , 5, 730-734	4
947	Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 1087-1088	59.2 19
946	Reply to Gautret et al: hydroxychloroquine sulfate and azithromycin for COVID-19: what is the evidence and what are the risks?. <b>2020</b> , 56, 106056	18
945	Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19. <b>2020</b> , 59, 176-190	44
944	Matrix metalloproteinase 9 as a host protein target of chloroquine and melatonin for immunoregulation in COVID-19: A network-based meta-analysis. <b>2020</b> , 257, 118096	24
943	Comprehensive Review on Current Interventions, Diagnostics, and Nanotechnology Perspectives against SARS-CoV-2. <b>2020</b> , 31, 2021-2045	36
942	Chloroquine and hydroxychloroquine in coronavirus disease 2019 (COVID-19). Facts, fiction and the hype: a critical appraisal. <b>2020</b> , 56, 106101	52
941	Pathogenesis and management of myocardial injury in coronavirus disease 2019. <b>2020</b> , 22, 1994-2006	19
940	Safety perspectives on presently considered drugs for the treatment of COVID-19. <b>2020</b> , 177, 4353-4374	9
939	Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID-19 Infection. <b>2020</b> , 108, 1135-1149	17
938	Insights in Chloroquine Action: Perspectives and Implications in Malaria and COVID-19. <b>2020</b> , 97, 872-881	6
937	Communicating Science in the Time of a Pandemic. <b>2020</b> ,	29
936	Coronavirus Disease-19: An Interim Evidence Synthesis of the World Association for Infectious Diseases and Immunological Disorders (Waidid). <b>2020</b> , 7, 572485	10
935	A Case Control Study to Evaluate the Impact of Colchicine on Patients Admitted to the Hospital with Moderate to Severe COVID-19 Infection. <b>2020</b> , 2020, 8865954	28
934	Chloroquine, hydroxychloroquine, and COVID-19: Systematic review and narrative synthesis of efficacy and safety. <b>2020</b> , 28, 1760-1776	14
933	Recent Clinical and Preclinical Studies of Hydroxychloroquine on RNA Viruses and Chronic Diseases: A Systematic Review. <b>2020</b> , 25,	2

932	Ophthalmic complaints in face-mask wearing: prevalence, treatment, and prevention with a potential protective effect against SARS-CoV-2. <b>2020</b> , 34, 1323-1335	6
931	Advances in the treatment of novel coronavirus disease (COVID-19) with Western medicine and traditional Chinese medicine: a narrative review. <b>2020</b> , 12, 6054-6069	7
930	Treatment Options for Coronavirus Disease 2019 in Patients With Reduced or Absent Kidney Function. <b>2020</b> , 27, 434-441	2
929	Hydroxychloroquine Inhibits the Trained Innate Immune Response to Interferons. <b>2020</b> , 1, 100146	13
928	Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19. <b>2020</b> , 29, 100645	34
927	Safe and effective medication utilization in pediatric patients requiring rehabilitation services during the Coronavirus pandemic of 2019. <b>2020</b> , 13, 221-223	2
926	COVID-19 Clinical Trials Registered Worldwide for Drug Intervention: An Overview and Characteristic Analysis. <b>2020</b> , 14, 5097-5108	4
925	Knowing more about chloroquine/hydroxychloroquine in COVID-19 patients. <b>2020</b> , 15, 1523-1526	3
924	Drug Repurposing Approaches to Combating Viral Infections. <b>2020</b> , 9,	9
923	Targeted intracellular degradation of SARS-CoV-2 via computationally optimized peptide fusions. <b>2020</b> , 3, 715	8
922	Hydroxychloroquine use and COVID-19 concerns among alopecia patients: A cross-sectional survey study. <b>2020</b> , 33, e14529	
921	Repurposing Anti-Cancer Drugs for COVID-19 Treatment. <b>2020</b> , 14, 5045-5058	14
920	Safety of Hydroxychloroquine Among Outpatient Clinical Trial Participants for COVID-19. <b>2020</b> , 7, ofaa500	26
919	Management of Pediatric Kidney Transplant Patients During the COVID-19 Pandemic: Guidance From the Canadian Society of Transplantation Pediatric Group. <b>2020</b> , 7, 2054358120967845	9
918	Management of Canadian Pediatric Patients With Glomerular Diseases During the COVID-19 Pandemic: Recommendations From the Canadian Association of Pediatric Nephrologists COVID-19 Rapid Response Team. <b>2020</b> , 7, 2054358120970713	2
917	The Saga of Hydroxychloroquine and COVID-19: A Cautionary Tale. <b>2020</b> , 173, 662-663	7
916	Re: Chloroquine (CQ) and Hydroxychloroquine (HQ) Retinal Toxicity Consideration in the Treatment of the Coronavirus Disease 2019 (COVID-19). <b>2020</b> , 9, 375-376	
915	Is Machine Learning a Better Way to Identify COVID-19 Patients Who Might Benefit from Hydroxychloroquine Treatment?-The IDENTIFY Trial. <b>2020</b> , 9,	6

914	Genomic evolution of severe acute respiratory syndrome Coronavirus 2 in India and vaccine impact. <b>2020</b> , 38, 210-212		4
913	Identification of an Antiviral Compound from the Pandemic Response Box that Efficiently Inhibits SARS-CoV-2 Infection In Vitro. <i>Microorganisms</i> , <b>2020</b> , 8,	4-9	14
912	Dose-Response Effects of Hydroxychloroquine on Prophylaxis Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection. <b>2021</b> , 73, e1771-e1772		1
911	Biology of COVID-19 and related viruses: Epidemiology, signs, symptoms, diagnosis, and treatment. <b>2021</b> , 35, 269-292		4
910	Coronavirus and Homo Sapiens in Coronavirus Disease 2019 (COVID-19). <b>2020</b> , 4, 121-131		
909	Risk Factors Associated With In-Hospital Mortality in a US National Sample of Patients With COVID-19. <b>2020</b> , 3, e2029058		178
908	Post-exposure prophylaxis with hydroxychloroquine for the prevention of COVID-19, a myth or a reality? The PEP-CQ Study. <b>2020</b> , 56, 106224		5
907	Impact of Hydroxychloroquine on Mortality in Hospitalized Patients with COVID-19: Systematic Review and Meta-Analysis. <b>2020</b> , 8,		4
906	Update Alert: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19. <b>2020</b> , 173, W78-W79		15
905	Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 : A Randomized Trial. <b>2020</b> , 173, 623-631		298
904	Does hydroxychloroquine reduce mortality for COVID-19?. <b>2020</b> , 82, 21-22		2
903	Controversies over hydroxychloroquine in the prevention of SARS-CoV-2 infection put rheumatologists on the frontline. <b>2020</b> , 6,		0
902	Pharmacophore modelling of vanillin derivatives, favipiravir, chloroquine, hydroxychloroquine, monolaurin and tetrodotoxin as M inhibitors of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). <b>2020</b> , 13, 527		8
901	COVID-19 and Systemic Lupus Erythematosus: Focus on Immune Response and Therapeutics. <b>2020</b> , 11, 589474		25
900	COVID-19 and sudden cardiac death: A new potential risk. <b>2020</b> , 72, 333-336		10
899	The COVID-19 pandemic: A community approach. <b>2020</b> , 34, e14059		7
898	Possible synergistic effects of hydroxychloroquine and steroids in COVID-19, time for a nuanced approach. Comment on Arshad et al. <b>2020</b> , 99, 344-345		1
897	Pathogenesis of SARS-CoV-2 induced cardiac injury from the perspective of the virus. <b>2020</b> , 147, 12-17		19

896	Medication therapy strategies for the coronavirus disease 2019 (COVID-19): recent progress and challenges. <b>2020</b> , 13, 957-975	5
895	COVID-19: a primer for the rheumatologist: management of patients and care settings. <b>2020</b> , 32, 429-433	2
894	Response to: 'Hydroxychloroquine ineffective for COVID-19 prophylaxis in lupus and rheumatoid arthritis' by Singer. <b>2020</b> ,	
893	Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past. <b>2020</b> , 11, 1949	163
892	Why is pre-exposure prophylaxis with hydroxychloroquine a safe and rationale approach against SARS-CoV-2 infection?. <b>2020</b> , 22, 864-865	2
891	The critical role of futility analysis in the pursuit of effective treatments for COVID-19. <b>2020</b> , 19, 100581	1
890	RE: "EARLY OUTPATIENT TREATMENT OF SYMPTOMATIC, HIGH-RISK COVID-19 PATIENTS THAT SHOULD BE RAMPED UP IMMEDIATELY AS KEY TO THE PANDEMIC CRISIS". <b>2020</b> , 189, 1443-1444	5
889	Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 2041-2052	59.2 620
888	THE AUTHOR REPLIES. <b>2020</b> , 189, 1444-1449	3
887	Beyond Anti-viral Effects of Chloroquine/Hydroxychloroquine. <b>2020</b> , 11, 1409	27
886	Leveraging the United States Epicenter to Provide Insights on COVID-19 in Patients With Systemic Lupus Erythematosus. <b>2020</b> , 72, 1971-1980	35
885	COVID-19: A Multidisciplinary Review. <b>2020</b> , 8, 383	61
884	Potential Anti-COVID-19 Therapeutics that Block the Early Stage of the Viral Life Cycle: Structures, Mechanisms, and Clinical Trials. <b>2020</b> , 21,	27
883	Guidelines for COVID-19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients. <b>2020</b> , 26, 1983-1994	26
882	Organ-specific manifestations of COVID-19 infection. <b>2020</b> , 20, 493-506	194
881	Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents. <b>2020</b> , 59, 1195-1216	18
880	Drug treatments for covid-19: living systematic review and network meta-analysis. <b>2020</b> , 370, m2980	331
879	Digitizing clinical trials. <b>2020</b> , 3, 101	58

878	Hydroxychloroquine Alternatives for Chronic Disease: Response to a Growing Shortage Amid the Global COVID-19 Pandemic. <b>2020</b> , 897190020942658	5
877	The Pharmacokinetic and Pharmacodynamic Properties of Hydroxychloroquine and Dose Selection for COVID-19: Putting the Cart Before the Horse. <b>2020</b> , 9, 561-572	15
876	Physicians' Perspectives on COVID-19: An International Survey. <b>2020</b> , 8,	6
875	COVID-19: An overview of the current pharmacological interventions, vaccines, and clinical trials. <b>2020</b> , 180, 114184	32
874	Cancer therapy and treatments during COVID-19 era. <b>2020</b> , 77, 100739	19
873	Rheumatologists' practice during the Coronavirus disease 2019 (COVID-19) pandemic: a survey in Egypt. <b>2020</b> , 40, 1599-1611	19
872	Chloroquine and hydroxychloroquine for COVID-19: time to close the chapter. <b>2021</b> , 97, 676-677	7
871	Immune Response and COVID-19: A mirror image of Sepsis. <b>2020</b> , 16, 2479-2489	32
870	Significant Unresolved Questions and Opportunities for Bioengineering in Understanding and Treating COVID-19 Disease Progression. <b>2020</b> , 13, 1-26	4
869	Antimalarials as Antivirals for COVID-19: Believe it or Not!. <b>2020</b> , 360, 618-630	14
868	Emerging therapeutics for the management of COVID 19. <b>2020</b> , 25, 337-351	5
867	A Systematic Review of Treatment and Outcomes of Pregnant Women With COVID-19-A Call for Clinical Trials. <b>2020</b> , 7, ofaa350	19
866	COVID-19 and Cardiovascular Health Among Patients with Cancer. <b>2020</b> , 22, 171	5
865	Antivirals for COVID-19 in Solid Organ Transplant Recipients. <b>2020</b> , 7, 1-11	4
864	Evaluation of mechanisms of action of re-purposed drugs for treatment of COVID-19. <b>2020</b> , 358, 104240	4
863	Current Options in the Treatment of COVID-19: A Review. <b>2020</b> , 13, 1999-2010	5
862	COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study. <b>2020</b> , 56, 106214	53
861	Response to: 'Correspondence on ': hydroxychloroquine, COVID-19and the role of the rheumatologist' by Graef ' by Lo. <b>2020</b> ,	1



860	PHARMACOLOGICAL TREATMENTS OF COVID-19 [A REVIEW. <b>2020</b> , 16-22	2
859	COVID-19 update: The race to therapeutic development. <b>2020</b> , 53, 100733	33
858	Moving fast but going slow: coordination challenges for trials of COVID-19 post-exposure prophylaxis. <b>2020</b> , 21, 815	1
857	Stabilizing Cellular Barriers: Raising the Shields Against COVID-19. <b>2020</b> , 11, 583006	3
856	Understanding the complexities of SARS-CoV2 infection and its immunology: A road to immune-based therapeutics. <b>2020</b> , 88, 106980	20
855	Targeting Crucial Host Factors of SARS-CoV-2. <b>2020</b> , 6, 2844-2865	13
854	COVID-19 in health-care workers: lessons from SARS and MERS epidemics and perspectives for chemoprophylaxis and vaccines. <b>2020</b> , 19, 937-947	7
853	COVID-19-Lessons Learned and Questions Remaining. <b>2021</b> , 72, 2225-2240	34
852	Recent Advances in Pathophysiology, Drug Development and Future Perspectives of SARS-CoV-2. <b>2020</b> , 8, 580202	19
851	A 21st Century Evil: Immunopathology and New Therapies of COVID-19. <b>2020</b> , 11, 562264	5
850	COVID-19 Pneumonia in Patients on Chronic Hydroxychloroquine Therapy: Three Cases of COVID-19 Pneumonia. <b>2020</b> , 2020, 8822753	3
849	Thinking about COVID-19 Scenario in Brazil: The Alternation between the Useful, the Uncertain and the Futile. <b>2020</b> , 42, 519-521	1
848	Clinical care of pregnant and postpartum women with COVID-19: Living recommendations from the National COVID-19 Clinical Evidence Taskforce. <b>2020</b> , 60, 840-851	18
847	The Regulatory Challenges for Drug Repurposing During the Covid-19 Pandemic: The Italian Experience. <b>2020</b> , 11, 588132	8
846	Hydroxychloroquine for coronavirus: how not to repurpose a drug during a pandemic. <b>2020</b> , 50, 1307-1310	2
845	Comment on 'Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19' by König . Long-term exposure to hydroxychloroquine or chloroquine and the risk of hospitalisation with COVID-19: a nationwide, observational cohort study in 54 873 exposed individuals and 155 689 matched unexposed	4
844	Statistical design of Phase II/III clinical trials for testing therapeutic interventions in COVID-19 patients. <b>2020</b> , 20, 220	3
843	Impact of Azithromycin and/or Hydroxychloroquine on Hospital Mortality in COVID-19. <b>2020</b> , 9,	19

842	COVID-19 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical pharmacology. <b>2020</b> , 17, e1003252		55
841	Antirheumatic drugs, B cell depletion and critical COVID-19: correspondence on 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine' by Mathian. <b>2020</b> ,		3
840	Chemoprophylaxis, diagnosis, treatments, and discharge management of COVID-19: An evidence-based clinical practice guideline (updated version). <b>2020</b> , 7, 41		37
839	Cell and animal models of SARS-CoV-2 pathogenesis and immunity. <b>2020</b> , 13,		26
838	Long-term hydroxychloroquine use in patients with rheumatic conditions and development of SARS-CoV-2 infection: a retrospective cohort study. <b>2020</b> , 2, e689-e697		29
837	Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults. <i>BMJ Open</i> , <b>2020</b> , 10, e041437	3	24
836	design, retrosynthetic analysis and combinatorial synthesis of a hybrid antiviral (VTAR-01) to inhibit the interaction of SARS-CoV2 spike glycoprotein with human angiotensin-converting enzyme 2. <b>2020</b> , 9,		6
835	Ivermectin as a Broad-Spectrum Host-Directed Antiviral: The Real Deal?. <b>2020</b> , 9,		37
834	SARS-CoV-2 pharmacologic therapies and their safety/effectiveness according to level of evidence. <b>2020</b> , 38, 2405-2415		10
833	Repurposing Immunomodulatory Therapies against Coronavirus Disease 2019 (COVID-19) in the Era of Cardiac Vigilance: A Systematic Review. <b>2020</b> , 9,		5
832	Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study. <b>2020</b> , 82, 38-47		64
831	A Pediatric Infectious Diseases Perspective of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Novel Coronavirus Disease 2019 (COVID-19) in Children. <b>2020</b> , 9, 596-608		18
830	Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). <b>2020</b> , 63, 13205-13227		18
829	Quality Assessment of the Chinese Clinical Trial Protocols Regarding Treatments for Coronavirus Disease 2019. <b>2020</b> , 11, 1330		
828	Epigenetic susceptibility to severe respiratory viral infections and its therapeutic implications: a narrative review. <b>2020</b> , 125, 1002-1017		20
827	Coronavirus Interplay With Lipid Rafts and Autophagy Unveils Promising Therapeutic Targets. <b>2020</b> , 11, 1821		33
826	Can We Test Our Way Out of the COVID-19 Pandemic?. <b>2020</b> , 58,		22
825	An Ounce of Prevention and a Pound of Cure: Randomized Clinical Trials of Therapeutics Against COVID-19 and an Assessment of Personal Protective Equipment and Distancing. <b>2020</b> , 108, 333-336		1

824	Probiotics and Coronavirus disease 2019: think about the link. <b>2021</b> , 126, 1564-1570	10
823	A Simple Bayesian Method for Evaluating Whether Data From Patients With Rheumatic Diseases Who Have Been Under Chronic Hydroxychloroquine Medication Since Before the COVID-19 Outbreak Can Speak to Hydroxychloroquine's Prophylactic Effect Against Infection With SARS-CoV-2. <b>2020</b> , 7, 490	
822	Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds. <b>2020</b> , 12,	32
821	Steroids and COVID-19: We Need a Precision Approach, Not One Size Fits All. <b>2020</b> , 9, 701-705	12
820	Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2. <b>2020</b> , 585, 588-590	243
819	Crosstalk between coronavirus disease 2019 and cardiovascular disease and its treatment. <b>2020</b> , 7, 3464	9
818	SARS-CoV-2 multifaceted interaction with human host. Part I: What we have learnt and done so far, and the still unknown realities. <b>2020</b> , 72, 2313-2330	7
817	Azithromycin for severe COVID-19. <b>2020</b> , 396, 936-937	42
816	Mutagenic, Genotoxic and Immunomodulatory effects of Hydroxychloroquine and Chloroquine: a review to evaluate its potential to use as a prophylactic drug against COVID-19. <b>2020</b> , 42, 25	8
815	[COVID-19 infection-update]. <b>2020</b> , 25, 1-8	
814	Methodological Issues and Controversies in COVID-19 Coagulopathy: A Tale of Two Storms. <b>2020</b> , 26, 1076029620945398	3
813	[Health crisis and reflexive crisis: The medical perspective in times of epidemic]. <b>2020</b> , 41, 507-509	1
812	Response to the Novel Corona Virus (COVID-19) Pandemic Across Africa: Successes, Challenges, and Implications for the Future. <b>2020</b> , 11, 1205	68
811	Therapeutic Strategies in the Development of Anti-viral Drugs and Vaccines Against SARS-CoV-2 Infection. <b>2020</b> , 57, 4856-4877	20
810	COVID-19 Therapeutic Options Under Investigation. <b>2020</b> , 11, 1196	49
809	On-target versus off-target effects of drugs inhibiting the replication of SARS-CoV-2. <b>2020</b> , 11, 656	24
808	Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 and SARS-CoV. <b>2020</b> , 94,	113
807	Hydroxychloroquine use in COVID-19: is the risk of cardiovascular toxicity justified?. <b>2020</b> , 7,	10

806	Chloroquine and hydroxychloroquine as a repurposed agent against COVID-19: a narrative review. <b>2020</b> , 7, 2049936120947517	9
805	Research Progress of Chloroquine and Hydroxychloroquine on the COVID-19 and Their Potential Risks in Clinic Use. <b>2020</b> , 11, 1167	8
804	A Narrative Review of Emerging Therapeutics for COVID-19. <b>2020</b> , 4, 745-758	5
803	Nano-Biomimetic Drug Delivery Vehicles: Potential Approaches for COVID-19 Treatment. <b>2020</b> , 25,	15
802	Development of vaccines and antivirals for combating viral pandemics. <b>2020</b> , 4, 1128-1133	27
801	Hydroxychloroquine as Prophylaxis for COVID-19: A Review. <b>2020</b> , 11, 605185	5
800	The contribution of the observational research design to COVID-19 research. <b>2020</b> , 2, e650-e652	1
799	Causal inference methods for small non-randomized studies: Methods and an application in COVID-19. <b>2020</b> , 99, 106213	4
798	It is time to drop hydroxychloroquine from our COVID-19 armamentarium. <b>2020</b> , 144, 110198	5
797	An update on COVID-19 pandemic: the epidemiology, pathogenesis, prevention and treatment strategies. <b>2021</b> , 19, 877-888	59
796	Inhibition of SARS-CoV-2 Entry into Host Cells Using Small Molecules. <b>2020</b> , 13,	12
795	Dealing with coronavirus disease 2019 (COVID-19) outbreaks in long-term care homes: A protocol for room moving and cohorting. <b>2021</b> , 42, 1402-1403	2
794	A Note From the Editors. <b>2020</b> , 189, 1215-1217	1
793	Highlights in the fight against COVID-19: does autophagy play a role in SARS-CoV-2 infection?. <b>2020</b> , 16, 2123-2127	16
792	Challenges for Drug Repurposing in the COVID-19 Pandemic Era. <b>2020</b> , 11, 588654	41
791	Misguided Use of Hydroxychloroquine for COVID-19: The Infusion of Politics Into Science. <b>2020</b> , 324, 2161-2162	43
790	Adverse drug reactions associated with concurrent acute psychiatric treatment and Covid-19 drug therapy. <b>2021</b> , 25, 142-146	1
789	Hydroxychloroquine for the Prevention of Covid-19 - Searching for Evidence. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 585-586	59.2 65

788	Autophagy as an emerging target for COVID-19: lessons from an old friend, chloroquine. <b>2020</b> , 16, 2260-2266	40
787	A compendium answering 150 questions on COVID-19 and SARS-CoV-2. <b>2020</b> , 75, 2503-2541	58
786	Potential implications of SARS-CoV-2 epidemic in Africa: where are we going from now?. <b>2020</b> , 20, 412	7
785	COVID-19 research: an opinion piece. <b>2020</b> , 21, 536-540	3
784	Deciphering the Role of Host Genetics in Susceptibility to Severe COVID-19. <b>2020</b> , 11, 1606	27
783	Timing of Antiviral Treatment Initiation is Critical to Reduce SARS-CoV-2 Viral Load. <b>2020</b> , 9, 509-514	93
782	Liraglutide for management of adolescent obesity. <b>2020</b> , 16, 405-406	1
781	Chloroquine and COVID-19: A western medical and scientific drift?. <b>2020</b> , 78, 4-5	3
780	Potential drug-drug interactions associated with drugs currently proposed for COVID-19 treatment in patients receiving other treatments. <b>2020</b> , 34, 530-547	19
779	Successful Treatment of Covid-19 Associated Cytokine Release Syndrome with Colchicine. A Case Report and Review of Literature. <b>2021</b> , 50, 884-890	9
778	Clinical Trials of Repurposed Antivirals for SARS-CoV-2. <b>2020</b> , 64,	26
777	Challenges of autoimmune rheumatic disease treatment during the COVID-19 pandemic: A review. <b>2020</b> , 75, 335-342	5
776	Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations. <b>2020</b> , 64,	35
775	COVID-19 and kidney transplantation: Results from the TANGO International Transplant Consortium. <b>2020</b> , 20, 3140-3148	165
774	Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19. <b>2020</b> , 16, 659-666	40
773	Kidney transplant patients with SARS-CoV-2 infection: The Brescia Renal COVID task force experience. <b>2020</b> , 20, 3019-3029	48
772	Mild or Moderate Covid-19. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 1757-1766	59.2 627
771	Response to: 'The role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients' by Favalli. <b>2021</b> , 80, e76	1

770	Still early to define a clear role of antimalarial drugs for COVID-19 in patients with rheumatic disease. Response to: 'Hydroxychloroquine reduces the risk of covid-19 in patients with rheumatic diseases: myth or reality?' by Xie. <b>2021</b> , 80, e7	4
769	Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection. <b>2021</b> , 93, 755-759	24
768	Coronavirus Disease 2019 (COVID-19) Pharmacologic Treatments for Children: Research Priorities and Approach to Pediatric Studies. <b>2021</b> , 72, 1067-1073	2
767	Response to: 'Concerns and needs of patients with systemic lupus erythematosus regarding hydroxychloroquine supplies during the COVID-19 pandemic: results from a patient-centred survey' by PLoS <b>2020</b> ,	
766	An overview on the use of antivirals for the treatment of patients with COVID19 disease. <b>2021</b> , 30, 45-59	1
765	An overview of antiviral strategies for coronavirus 2 (SARS-CoV-2) infection with special reference to antimalarial drugs chloroquine and hydroxychloroquine. <b>2021</b> , 75, e13825	5
764	Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform. <b>2021</b> , 3, e19-e27	28
763	Hydroxychloroquine for the treatment and prophylaxis of COVID-19: The journey so far and the road ahead. <b>2021</b> , 890, 173717	14
762	Hydroxychloroquine for Prevention of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: Challenges to Trial Conduct During the Global Pandemic. <b>2021</b> , 72, e844-e847	2
761	A district-level susceptibility and vulnerability assessment of the COVID-19 pandemic's footprint in India. <b>2021</b> , 36, 100390	7
760	A Strategy to Treat COVID-19 Disease With Targeted Delivery of Inhalable Liposomal Hydroxychloroquine: A Preclinical Pharmacokinetic Study. <b>2021</b> , 14, 132-136	22
759	Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries. <b>2020</b> ,	26
758	Step toward repurposing drug discovery for COVID-19 therapeutics through in silico approach. <b>2021</b> , 82, 374-392	5
757	Hydroxychloroquine in the COVID-19 pandemic era: in pursuit of a rational use for prophylaxis of SARS-CoV-2 infection. <b>2021</b> , 19, 5-16	15
756	Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-Analysis. <b>2021</b> , 73, 36-47	34
755	Emerging Human Coronavirus Infections (SARS, MERS, and COVID-19): Where They Are Leading Us. <b>2021</b> , 40, 5-53	13
754	Reply to Million et al. <b>2021</b> , 72, e440-e441	
753	Susceptibility to COVID-19 in Patients Treated With Antimalarials: A Population-Based Study in Emilia-Romagna, Northern Italy. <b>2021</b> , 73, 48-52	5

752	Safety of hydroxychloroquine in COVID-19 and other diseases: a systematic review and meta-analysis of 53 randomized trials. <b>2021</b> , 77, 13-24	9
751	Clinical trial protocols of repurposed prophylaxis for COVID-19: A review. <b>2021</b> , 51, 7-13	3
750	Chloroquine and hydroxychloroquine in the prophylaxis and therapy of COVID-19 infection. <b>2021</b> , 538, 156-162	4
749	Chloroquine and hydroxychloroquine for COVID-19: Perspectives on their failure in repurposing. <b>2021</b> , 46, 17-27	14
748	The association of smoking status with SARS-CoV-2 infection, hospitalization and mortality from COVID-19: a living rapid evidence review with Bayesian meta-analyses (version 7). <b>2021</b> , 116, 1319-1368	136
747	Antiviral therapies: advances and perspectives. <b>2021</b> , 35, 305-320	10
746	Hydroxychloroquine as Pre-exposure Prophylaxis for Coronavirus Disease 2019 (COVID-19) in Healthcare Workers: A Randomized Trial. <b>2021</b> , 72, e835-e843	59
745	Immunity, endothelial injury and complement-induced coagulopathy in COVID-19. <b>2021</b> , 17, 46-64	209
744	Modeling COVID-19 scenarios for the United States. <b>2021</b> , 27, 94-105	190
743	Pathogenesis-directed therapy of 2019 novel coronavirus disease. <b>2021</b> , 93, 1320-1342	22
742	Experience of the use of hydroxychloroquine on patients with COVID-19: A perspective on viral load and cytokine kinetics. <b>2021</b> , 120, 1269-1273	2
741	Clinical risk factors for mortality in patients with cancer and COVID-19: a systematic review and meta-analysis of recent observational studies. <b>2021</b> , 21, 107-119	16
740	Review on therapeutic targets for COVID-19: insights from cytokine storm. <b>2021</b> , 97, 391-398	11
739	Implications of the COVID-19 Pandemic for Cardiovascular Disease and Risk-Factor Management. <b>2021</b> , 37, 722-732	12
738	Prevention and treatment of COVID-19: Focus on interferons, chloroquine/hydroxychloroquine, azithromycin, and vaccine. <b>2021</b> , 133, 111008	14
737	Hydroxychloroquine pre-exposure prophylaxis for COVID-19 in healthcare workers. <b>2021</b> , 76, 827-829	6
736	Dendritic cells in COVID-19 immunopathogenesis: insights for a possible role in determining disease outcome. <b>2021</b> , 40, 108-125	24
735	A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 417-427	59.2 108

734	Safety of hydroxychloroquine for treatment or prevention of SARS-CoV-2 infection: A rapid systematic review and meta-analysis of randomized clinical trials. <b>2021</b> , 9, 31-36	5
733	COVID-19 and rheumatic musculoskeletal disease patients: infection rates, attitudes and medication adherence in an Irish population. <b>2021</b> , 60, 902-906	7
732	Insights into disparities observed with COVID-19. <b>2021</b> , 289, 463-473	40
731	Hydroxychloroquine in the prevention of COVID-19 mortality. <b>2021</b> , 3, e2-e3	18
730	Safety and efficacy of hydroxychloroquine in 152 outpatients with confirmed COVID-19: A pilot observational study. <b>2021</b> , 40, 41-46	14
729	Zoonotic coronavirus epidemics: Severe acute respiratory syndrome, Middle East respiratory syndrome, and coronavirus disease 2019. <b>2021</b> , 126, 321-337	6
728	COVID19- clinical presentation and therapeutic considerations. <b>2021</b> , 538, 125-131	9
727	Effect of hydroxychloroquine pre-exposure on infection with SARS-CoV-2 in rheumatic disease patients: a population-based cohort study. <b>2021</b> , 27, 611-617	12
726	Recent Insights into Emerging Coronavirus: SARS-CoV-2. <b>2021</b> , 7, 1369-1388	13
725	COVID-19 and Multisystem Inflammatory Syndrome in Latin American Children: A Multinational Study. <b>2021</b> , 40, e1-e6	58
724	Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection : A Randomized Trial. <b>2021</b> , 174, 344-352	36
723	A First Draft of the History of Treating Coronavirus Disease 2019: Use of Repurposed Medications in United States Hospitals. <b>2021</b> , 8, ofaa617	1
722	A Revisit to the Research Updates of Drugs, Vaccines, and Bioinformatics Approaches in Combating COVID-19 Pandemic. <b>2020</b> , 7, 585899	6
721	COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease. <b>2021</b> , 232, 13-36	26
720	Access to data from clinical trials in the COVID-19 crisis: open, flexible, and time-sensitive. <b>2021</b> , 130, 143-146	10
719	COVID-19 and Solid Organ Transplantation: A Review Article. <b>2021</b> , 105, 37-55	111
718	Optimizing peer review to minimize the risk of retracting COVID-19-related literature. <b>2021</b> , 24, 21-26	10
717	The Decline of the Experimental Paradigm During the COVID-19 Pandemic: A Template for the Future. <b>2021</b> , 134, 166-175	7



716	Challenges of drug development during the COVID-19 pandemic: Key considerations for clinical trial designs. <b>2021</b> , 87, 2170-2185	7
715	Emerging treatment strategies for COVID-19 infection. <b>2021</b> , 21, 167-179	81
714	Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial. <b>2021</b> , 181, 195-202	102
713	Rational for meta-analysis and randomized treatment: the COVID-19 example. <b>2021</b> , 27, 6-8	4
712	Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019. <b>2021</b> , 53, 117-134	26
711	An enlightening role for cytokine storm in coronavirus infection. <b>2021</b> , 222, 108615	19
710	Recent progress of antiviral therapy for coronavirus disease 2019. <b>2021</b> , 890, 173646	16
709	Clinical Characteristics, Treatment, and Outcomes of Critically Ill Patients With COVID-19: A Scoping Review. <b>2021</b> , 96, 183-202	30
708	Beyond dexamethasone, emerging immuno-thrombotic therapies for COVID-19. <b>2021</b> , 87, 845-857	3
707	Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose. <b>2021</b> , 59, 12-23	24
706	Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre-COVID-19 reports. <b>2021</b> , 87, 1432-1442	26
705	Hydroxychloroquine early in pregnancy and risk of birth defects. <b>2021</b> , 224, 290.e1-290.e22	15
704	Assessing QT interval in COVID-19 patients:safety of hydroxychloroquine-azithromycin combination regimen. <b>2021</b> , 324, 242-248	12
703	Pregnancy and COVID-19: pharmacologic considerations. <b>2021</b> , 57, 195-203	23
702	Hydroxychloroquine use and progression or prognosis of COVID-19: a systematic review and meta-analysis. <b>2021</b> , 394, 775-782	10
701	Immunopathology of Hyperinflammation in COVID-19. <b>2021</b> , 191, 4-17	143
700	Multicenter Interim Guidance on Use of Antivirals for Children With Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2. <b>2021</b> , 10, 34-48	37
699	SARS-CoV-2: Mechanism of infection and emerging technologies for future prospects.. <b>2021</b> , 31, e2168	14

698	Hydroxychloroquine in the post-COVID-19 era: will this pandemic upset decades of clinical practice?. <b>2021</b> , 40, 1649-1657	1
697	Drug Discovery by Drug Repurposing: Combating COVID-19 in the 21st Century. <b>2021</b> , 21, 3-9	4
696	Hidden in plain sight: sex and gender in global pandemics. <b>2021</b> , 16, 48-53	2
695	COVID-19-neutralizing antibodies predict disease severity and survival. <b>2021</b> , 184, 476-488.e11	270
694	Lysosomotropic agents including azithromycin, chloroquine and hydroxychloroquine activate the integrated stress response. <b>2021</b> , 12, 6	7
693	A literature review of consent declines and consent withdrawals in randomized controlled trials conducted during the COVID-19 pandemic. <b>2021</b> , 67, 134-138	1
692	Hydroxychloroquine Plus Standard Personal Protective Equipment Versus Standard Personal Protective Equipment Alone for the Prevention of Laboratory Confirmed Covid-19 Infections Among Healthcare Workers: A Multi-Centre Parallel Group Randomized Controlled Trial from India.	
691	COVID-19 in Association With Development, Course, and Treatment of Systemic Autoimmune Rheumatic Diseases. <b>2020</b> , 11, 611318	8
690	Sialylation of host proteins as targetable risk factor for COVID-19 susceptibility and spreading: A hypothesis. <b>2021</b> , 3, 192-197	0
689	THE CHALLENGING AND UNPREDICTABLE SPECTRUM OF COVID-19 IN CHILDREN AND ADOLESCENTS. <b>2020</b> , 39, e2020192	15
688	Let's do better: public representations of COVID-19 science. <b>2021</b> , 6, 403-423	7
687	COVID-19: can we treat the mother without harming her baby?. <b>2021</b> , 1-11	2
686	COVID-19 and cardiovascular disease: Clinical implications of biochemical pathways. <b>2021</b> , 7, 97	1
685	Emerging therapeutics in the management of COVID-19. <b>2021</b> , 10, 1-29	2
684	[S2k Guideline - Recommendations for Inpatient Therapy of Patients with COVID-19]. <b>2021</b> , 75, 88-112	14
683	Current Evidence on Coronavirus Disease-2019: A Comprehensive Review. <b>2021</b> , 3, 65-73	1
682	COVID-19 Pandemisinde Kullanılan İlaçlar, Etki Mekanizmaları ve Etkililikleri. 00,	0
681	Hydroxychloroquine in the prophylaxis of COVID 19: A survey of safety on the healthcare workers in India. <b>2021</b> , 12, 58-59	3

680 Mask mandates in light of DANMASK-19. **2021**, 1-2

679 Pathogenesis of Multiple Organ Injury in COVID-19 and Potential Therapeutic Strategies. **2021**, 12, 593223 42

678 Hydroxychloroquine/Chloroquine as Therapeutics for COVID-19: Truth under the Mystery. **2021**, 17, 1538-1546 12

677 Safety of pharmacological options for the management of COVID-19 in pregnant women: An Indian perspective. **2021**, 32, 3-17 3

676 Chloroquine nasal drops in asymptomatic & mild COVID-19: An exploratory randomized clinical trial. **2021**, 153, 151-158 4

675 Efficacy of GC-376 against SARS-CoV-2 virus infection in the K18 hACE2 transgenic mouse model. **2021**, 5

674 Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2. **2021**, 17, e1009212 85

673 Serosurvey for Health-Care Workers Provides Supportive Evidence for the Effectiveness of Hydroxychloroquine Prophylaxis against SARS-CoV-2 Infection. **2021**, 11, 283-288 2

672 Convalescent plasma and hyperimmune immunoglobulin to prevent infection with SARS-CoV-2. 1

671 Clinical course and challenging management of early COVID-19 infection after heart transplantation: case report of two patients. **2021**, 21, 89 6

670 From hydroxychloroquine to ivermectin: what are the anti-viral properties of anti-parasitic drugs to combat SARS-CoV-2?. **2021**, 28, 11

669 Authors' response. **2021**, 153, 565-567

668 Filling the Gap Until Full Vaccine Deployment in the War on Coronavirus Disease-19. **2021**, 10, 27-34 1

667 Translating evidence into practice during the COVID-19 pandemic: pitfalls and mileages. **2021**, 12, 2042098621998876

666 Severe COVID-19 infection in a patient with paroxysmal nocturnal hemoglobinuria on eculizumab therapy. **2021**, 62, 1502-1505 2

665 Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants. **2021**, 10, 1227-1240 3

664 COVID-19 and related symptoms in patients under disulfiram for alcohol use disorder. **2021**, 16, 1729-1731 5

663 Modeling drug mechanism of action with large scale gene-expression profiles using GPAR, an artificial intelligence platform. **2021**, 22, 17 8

662	A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent. <b>2021</b> , 28, 202-209	46
661	A prospective, observational study to evaluate adverse drug reactions in patients with COVID-19 treated with remdesivir or hydroxychloroquine: a preliminary report. <b>2021</b> , 28, 248-253	10
660	COVID-19 pathogenesis, prognostic factors, and treatment strategy: Urgent recommendations. <b>2021</b> , 93, 2694-2704	9
659	ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up. <b>2021</b> ,	28
658	SARS-CoV-2 Mediated Endothelial Dysfunction: The Potential Role of Chronic Oxidative Stress. <b>2020</b> , 11, 605908	37
657	Aging, Immunity, and COVID-19: How Age Influences the Host Immune Response to Coronavirus Infections?. <b>2020</b> , 11, 571416	126
656	A review on the advancements in the development of vaccines to combat coronavirus disease 2019. <b>2021</b> , 10, 6-12	7
655	Examination of patient characteristics and hydroxychloroquine use based on the US Food and Drug Administration's recommendation: a cross-sectional analysis in New York. <i>BMJ Open</i> , <b>2021</b> , 11, e042965 <sup>3</sup>	2
654	Therapeutic Strategies in the Management of COVID-19. <b>2020</b> , 7, 636738	8
653	COVID-19 and Its Implications for Thrombosis and Anticoagulation. <b>2021</b> , 42, 316-326	7
652	Methodological quality of COVID-19 clinical research. <b>2021</b> , 12, 943	30
651	Atteintes pulmonaires liées à la COVID-19. <b>2021</b> , 2, 14-24	0
650	Modalities and Mechanisms of Treatment for Coronavirus Disease 2019. <b>2020</b> , 11, 583914	4
649	Evolution of COVID-19 management in critical care: review and perspective from a hospital in the United Kingdom. <b>2021</b> , 36, 1-14	2
648	Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: A matched case-control study. <i>PLoS ONE</i> , <b>2021</b> , 16, e0247163	3-7 27
647	Drug Repurposing in the COVID-19 Era: Insights from Case Studies Showing Pharmaceutical Peculiarities. <b>2021</b> , 13,	11
646	Intensive care management of patients with COVID-19: a practical approach. <b>2021</b> , 11, 36	28
645	Open-source hardware to face COVID-19 pandemic: the need to do more and better. 1	

644	An updated systematic review and network meta-analysis of 25 randomized trials assessing the efficacy and safety of treatments in COVID-19 disease. <b>2021</b> , 10, 1945	2
643	Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19. <b>2021</b> , 2, CD013587	57
642	The papain-like protease of coronaviruses cleaves ULK1 to disrupt host autophagy. <b>2021</b> , 540, 75-82	12
641	Clinical features and outcomes of hospitalized COVID-19 patients in a low burden region. <b>2021</b> , 115, 243-249	3
640	Effectiveness of early therapeutic intervention in phases one and two after COVID-19 infection: systematic review. <b>2021</b> , 67, 302-312	
639	COVID-19: Understanding Inter-Individual Variability and Implications for Precision Medicine. <b>2021</b> , 96, 446-463	23
638	Antiviral activity of influenza A virus defective interfering particles against SARS-CoV-2 replication in vitro through stimulation of innate immunity.	1
637	Mesenchymal stem cell-derived exosomes for organ development and cell-free therapy. <b>2021</b> , 2, 1291-1325	1
636	The efficiency and safety of high-dose vitamin C in patients with COVID-19: a retrospective cohort study. <b>2021</b> , 13, 7020-7034	27
635	Akt-independent effects of triciribine on ACE2 expression in human lung epithelial cells: Potential benefits in restricting SARS-CoV2 infection. <b>2021</b> , 236, 6597-6606	3
634	Examining reporting and representation of patients with cancer in COVID-19 clinical trials. <b>2021</b> , 4, e1355	0
633	A Comprehensive Review of Viral Characteristics, Transmission, Pathophysiology, Immune Response, and Management of SARS-CoV-2 and COVID-19 as a Basis for Controlling the Pandemic. <b>2021</b> , 12, 631139	43
632	TLR Agonists as Mediators of Trained Immunity: Mechanistic Insight and Immunotherapeutic Potential to Combat Infection. <b>2020</b> , 11, 622614	24
631	The Rheumatology Drugs for COVID-19 Management: Which and When?. <b>2021</b> , 10,	8
630	Understanding Viral Infection Mechanisms and Patient Symptoms for the Development of COVID-19 Therapeutics. <b>2021</b> , 22,	5
629	Balancing clinical evidence in the context of a pandemic. <b>2021</b> , 39, 270-274	1
628	Gestione del Covid-19 in et^ pediatrica: documento di consenso. <b>2021</b> , 40, 85-101	4
627	Real-World Evidence for Assessing Pharmaceutical Treatments in the Context of COVID-19. <b>2021</b> , 109, 816-828	3

626	Balancing Healthcare and Economy Amidst the COVID-19 Pandemic: An Indian Experience. <b>2021</b> , 14, 827-833	3
625	Chyawanprash for the prevention of COVID-19 infection among healthcare workers: A Randomized Controlled Trial.	4
624	Recent Hydroxychloroquine Use Is Not Significantly Associated with Positive PCR Results for SARS-CoV-2: A Nationwide Observational Study in South Korea. <b>2021</b> , 13,	2
623	Harnessing biomaterials for therapeutic strategies against COVID-19. <b>2021</b> , 4, 1-10	3
622	Efficacy and safety of Ivermectin and Hydroxychloroquine in patients with severe COVID-19. A randomized controlled trial.	10
621	Use of hydroxychloroquine and chloroquine in patients with COVID-19: a meta-analysis of randomized clinical trials. <b>2021</b> , 115, 139-150	10
620	Using Medicare Data to Assess the Proarrhythmic Risk of Non-Cardiac Treatment Drugs that Prolong the QT Interval in Older Adults: An Observational Cohort Study. <b>2021</b> , 8, 173-185	2
619	Modeling the Effect of Population-Wide Vaccination on the Evolution of COVID-19 Epidemic in Canada.	4
618	A genome-wide CRISPR screen identifies host factors that regulate SARS-CoV-2 entry. <b>2021</b> , 12, 961	79
617	Prophylaxis for covid-19: living systematic review and network meta-analysis.	3
616	Low Zinc Levels at Admission Associates with Poor Clinical Outcomes in SARS-CoV-2 Infection. <b>2021</b> , 13,	39
615	Self-Reported Symptoms in a Cohort of Rheumatoid Arthritis and Systemic Lupus Erythematosus during the COVID-19 Quarantine Period. <b>2021</b> , 15, 16-23	0
614	Modeling of SARS-CoV-2 Treatment Effects for Informed Drug Repurposing. <b>2021</b> , 12, 625678	7
613	Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19. <b>2021</b> , 174, 433-434	
612	Prospective observational study of SARS-CoV-2 infection, transmission and immunity in a cohort of households in Liverpool City Region, UK (COVID-LIV): a study protocol. <i>BMJ Open</i> , <b>2021</b> , 11, e048317	3 1
611	Personalized prescription of ACEI/ARBs for hypertensive COVID-19 patients. <b>2021</b> , 24, 339-355	1
610	Hydroxychloroquine for the treatment of COVID-19 and its potential cardiovascular toxicity: Hero or villain?. <b>2021</b> , 35, 101658	2
609	Evaluation of the Current Therapeutic Approaches for COVID-19: A Systematic Review and a Meta-analysis. <b>2021</b> , 12, 607408	10

608	The impact of SARS-CoV-2 coronavirus infection in patients with systemic lupus erythematosus from a single center in Catalonia. <b>2021</b> , 40, 2057-2063		4
607	Pharmacological strategies to prevent SARS-CoV-2 infection and treat the early phases of COVID-19. <b>2021</b> , 104, 441-451		10
606	Chloroquine may induce endothelial injury through lysosomal dysfunction and oxidative stress. <b>2021</b> , 414, 115412		7
605	Repurposing Quinoline and Artemisinin Antimalarials as Therapeutics for SARS-CoV-2: Rationale and Implications. <b>2021</b> , 4, 613-623		3
604	Incidence of COVID-19 in patients exposed to chloroquine and hydroxychloroquine: results from a population-based prospective cohort in Catalonia, Spain, 2020. <b>2021</b> , 26,		2
603	A Retrospective Analysis of the Impact of the Coronavirus Disease 2019 Pandemic on Health Care Workers in a Tertiary Hospital in Turkey. <b>2021</b> , 47, 948-954		
602	Easing COVID-19 lockdown measures while protecting the older restricts the deaths to the level of the full lockdown. <b>2021</b> , 11, 5839		11
601	Torsades de pointes in SARS-CoV-2 (COVID-19) pneumonia: medicine reconciliation and careful monitoring of QTc interval may help prevent cardiac complications. <b>2021</b> , 14,		4
600	Development and validation of an LC-MS/MS method for determination of hydroxychloroquine, its two metabolites, and azithromycin in EDTA-treated human plasma. <i>PLoS ONE</i> , <b>2021</b> , 16, e0247356	3.7	1
599	Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen. <b>2021</b> , 12, 646676		17
598	Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. <b>2021</b> , 397, 1063-1074		105
597	Revising the Blype Pipeline Model in Scientific Communication. <b>2021</b> , 6,		0
596	Considerations of the effects of commonly investigated drugs for COVID-19 in the cholesterol synthesis pathway. <b>2021</b> , 22, 947-952		1
595	COVID-19 in Brazil: A Message to the World. <b>2021</b> , 43, 238-239		1
594	A Review of the Progress of COVID-19 Vaccine Development.		1
593	Association of prescribed medications with the risk of COVID-19 infection and severity among adults in South Korea. <b>2021</b> , 104, 7-14		9
592	Current evidence for COVID-19 therapies: a systematic literature review. <b>2021</b> , 30,		11
591	Renal Manifestations of Covid-19: Physiology and Pathophysiology. <b>2021</b> , 10,		9

590	A living WHO guideline on drugs to prevent covid-19. <b>2021</b> , 372, n526	31
589	A pilot double-blind safety and feasibility randomized controlled trial of high-dose intravenous zinc in hospitalized COVID-19 patients. <b>2021</b> , 93, 3261-3267	13
588	Effects of chloroquine or hydroxychloroquine treatment on non-SARS-CoV2 viral infections: A systematic review of clinical studies. <b>2021</b> , 31, e2228	4
587	The in-vitro effect of famotidine on sars-cov-2 proteases and virus replication. <b>2021</b> , 11, 5433	12
586	Comparison of Saliva and Nasopharyngeal Swab Nucleic Acid Amplification Testing for Detection of SARS-CoV-2: A Systematic Review and Meta-analysis. <b>2021</b> , 181, 353-360	128
585	Global COVID-19 pandemic and reporting behavior - An analysis of the Food and Drug Administration adverse events reporting system. <b>2021</b> , 30, 707-715	3
584	Efficacy of the combination of modern medicine and traditional Chinese medicine in pulmonary fibrosis arising as a sequelae in convalescent COVID-19 patients: a randomized multicenter trial. <b>2021</b> , 10, 31	5
583	Does hydroxychloroquine still have any role in the COVID-19 pandemic?. <b>2021</b> , 22, 1257-1266	4
582	Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine, and Pyronaridine: Activity against SARS-CoV-2 and Potential Mechanisms. <b>2021</b> , 6, 7454-7468	20
581	Coronil, a Tri-Herbal Formulation, Attenuates Spike-Protein-Mediated SARS-CoV-2 Viral Entry into Human Alveolar Epithelial Cells and Pro-Inflammatory Cytokines Production by Inhibiting Spike Protein-ACE-2 Interaction. <b>2021</b> , 14, 869-884	11
580	Bromhexine Hydrochloride Prophylaxis of COVID-19 for Medical Personnel: A Randomized Open-Label Study.	4
579	COVID-19 therapeutics for low- and middle-income countries: a review of re-purposed candidate agents with potential for near-term use and impact.	1
578	Baseline use of hydroxychloroquine or immunosuppressive drugs and the risk of coronavirus disease 2019. <b>2021</b> ,	1
577	4-Aminoquinoline compounds from the Spanish flu to COVID-19. <b>2021</b> , 135, 111138	3
576	Hydroxychloroquine Effects on TLR Signalling: Underexposed but Unneglectable in COVID-19. <b>2021</b> , 2021, 6659410	2
575	Clinical trial preparations for the next pandemic. <b>2021</b> , 102, 106292	1
574	Post-exposure prophylaxis against SARS-CoV-2 in close contacts of confirmed COVID-19 cases (CORIPREV): study protocol for a cluster-randomized trial. <b>2021</b> , 22, 224	4
573	Experimental therapies under investigation for COVID-19. <b>2021</b> , 11, 187-193	2



572	COVID-19 and obesity: what is known about the features of pathogenesis and treatment?. <b>2021</b> , 2, 17-23	1
571	First and second wave of coronavirus-19 disease: A comparative study in patients hospitalized in an ICU of a third-level university hospital. <b>2021</b> ,	0
570	Plasma IL-6 levels following corticosteroid therapy as an indicator of ICU length of stay in critically ill COVID-19 patients. <b>2021</b> , 7, 55	10
569	COVID-19: Antiviral agents and enzyme inhibitors/receptor blockers in development. <b>2021</b> , 246, 1533-1540	1
568	Precision therapeutic targets for COVID-19. <b>2021</b> , 18, 66	15
567	COVID-19 preparedness: capacity to manufacture vaccines, therapeutics and diagnostics in sub-Saharan Africa. <b>2021</b> , 17, 24	7
566	The first 12 months of COVID-19: a timeline of immunological insights. <b>2021</b> , 21, 245-256	140
565	Reply to the Letter to Editor by Lacout and colleagues: Chloroquine and Hydroxychloroquine for the Treatment of COVID-19: a Systematic Review and Meta-analysis. <b>2021</b> , 36, 2468-2469	
564	Obesity is a Major Risk Factor for Hospitalization in Community-Managed COVID-19 Pneumonia. <b>2021</b> , 96, 921-931	4
563	Prophylaxis for COVID-19: a systematic review. <b>2021</b> , 27, 532-537	12
562	Repositioned Drugs for COVID-19-the Impact on Multiple Organs. <b>2021</b> , 3, 1-18	3
561	COVID-19 Vaccination Scenarios: A Cost-Effectiveness Analysis for Turkey. <b>2021</b> , 9,	11
560	Current and New Drugs for COVID-19 Treatment and Its Effects on the Liver. <b>2021</b> , 9, 436-446	3
559	Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment. <b>2021</b> , 24, 102367	34
558	Robust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies. <b>2021</b> , 29, 551-563.e5	42
557	Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2. <b>2021</b> , 35, 108959	77
556	QTc prolongation in COVID-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta-analysis. <b>2021</b> , 30, 694-706	13
555	Nanocarrier vaccines for SARS-CoV-2. <b>2021</b> , 171, 215-239	37

554	Mortality in mechanically ventilated patients with COVID-19: a systematic review. <b>2021</b> , 18, 457-471	4
553	Deep Transfer Learning Approach for Automatic Recognition of Drug Toxicity and Inhibition of SARS-CoV-2. <b>2021</b> , 13,	3
552	System for administering and monitoring hydroxychloroquine prophylaxis for COVID-19 in accordance with a national advisory: preliminary experience of a tertiary care institute in India. <b>2021</b> , 19, 1331-1339	2
551	Chloroquine and Hydroxychloroquine for the Prevention and Treatment of COVID-19: A Fiction, Hope or Hype? An Updated Review. <b>2021</b> , 17, 371-387	31
550	Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19: The TOGETHER Randomized Clinical Trial. <b>2021</b> , 4, e216468	50
549	An open-label randomized controlled trial evaluating the efficacy of chloroquine/hydroxychloroquine in severe COVID-19 patients. <b>2021</b> , 11, 9023	21
548	Prophylaxis against covid-19: living systematic review and network meta-analysis. <b>2021</b> , 373, n949	31
547	Perspectives on Virtual (Remote) Clinical Trials as the "New Normal" to Accelerate Drug Development. <b>2021</b> ,	3
546	The Reply. <b>2021</b> , 134, e300	
545	COVID-19: Antiviral Tedavi.	
544	Prioritizing studies of COVID-19 and lessons learned. <b>2021</b> , 5, e106	3
543	The triple aim of clinical research. <b>2021</b> , 18, 511-513	1
542	The use of medicinal plants to prevent COVID-19 in Nepal. <b>2021</b> , 17, 26	26
541	Clinical outcomes of COVID-19 in patients with rheumatic diseases: A systematic review and meta-analysis of global data. <b>2021</b> , 20, 102778	17
540	COVID-19 and Disease-Modifying Anti-rheumatic Drugs. <b>2021</b> , 23, 28	7
539	Nearly Fatal Hydroxychloroquine Overdose Successfully Treated with Midazolam, Propofol, Sodium Bicarbonate, Norepinephrine, and Intravenous Lipid Emulsion. <b>2021</b> , 2021, 8876256	1
538	The treatment of SARS-CoV2 with antivirals and mitigation of the cytokine storm syndrome: the role of gene expression. <b>2021</b> , 64, 400-415	
537	Publications and retracted articles of COVID-19 pharmacotherapy-related research: A systematic review. <i>Science Progress</i> , <b>2021</b> , 104, 368504211016936	1.1 2

536	Folic acid as placebo in controlled clinical trials of hydroxychloroquine prophylaxis in COVID-19: Is it scientifically justifiable?. <b>2021</b> , 149, 110539		6
535	Ethical dimensions in randomized trials and off-label use of investigational drugs for COVID-19 treatment. 147775092110114		0
534	Revisõ Sobre O Uso Da Cloroquina E Da Hidroxicloroquina No Tratamento Dos Pacientes Acometidos Pela Covid-19. 43-64		
533	Novel Human Lung Tissue Model for the Study of SARS-CoV-2 Entry, Inflammation and New Therapeutics.		1
532	A review on the clinical trials of repurposing therapeutic drugs, mechanisms and preventive measures against SARS-CoV-2. <b>2021</b> ,		
531	The Role of Conspiracy Theories in the Spread of COVID-19 across the United States. <b>2021</b> , 18,		6
530	Molecular Dynamic Simulation Search for Possible Amphiphilic Drug Discovery for Covid-19. <b>2021</b> , 26,		
529	Risk of coronavirus disease 2019 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional disease-modifying anti-rheumatic drugs in Italy. <b>2021</b> , 60, S125-S136		5
528	Pandemic Perspectives on Medicine and Militarism. <b>2021</b> , 11, 252-270		1
527	Current COVID-19 treatments: Rapid review of the literature. <b>2021</b> , 11, 10003		13
526	Efficacy of a nasal spray containing Iota-Carrageenan in the prophylaxis of COVID-19 in hospital personnel dedicated to patients care with COVID-19 disease A pragmatic multicenter, randomized, double-blind, placebo-controlled trial (CARR-COV-02).		5
525	Assessing the efficacy and safety of hydroxychloroquine as outpatient treatment of COVID-19: a randomized controlled trial. <b>2021</b> , 9, E693-E702		7
524	The time to offer treatments for COVID-19. <b>2021</b> , 30, 505-518		9
523	Seroprevalence of antibodies to SARS-CoV-2 and predictors of seropositivity among employees of a teaching hospital in New Delhi, India. <b>2021</b> , 12, 88-95		2
522	Similar incidence of coronavirus disease 2019 (COVID-19) in patients with rheumatic diseases with and without hydroxychloroquine therapy. <i>PLoS ONE</i> , <b>2021</b> , 16, e0249036	3-7	1
521	A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19. <b>2021</b> , 21, 675-686		8
520	COVID-19 Management in the Pediatric Age: Consensus Document of the COVID-19 Working Group in Paediatrics of the Emilia-Romagna Region (RE-CO-Ped), Italy. <b>2021</b> , 18,		13
519	How Are Emerging Data Translated Into Clinical Practice? A Mixed Methods Investigation of Coronavirus Disease 2019 Institutional Treatment Protocols. <b>2021</b> , 8, ofab072		4

518	Moments in autophagy and disease: Past and present. <b>2021</b> , 82, 100966		7
517	Fast prototyping of a local fuzzy search system for decision support and retraining of hospital staff during pandemic. <b>2021</b> , 9, 21		1
516	Randomised, double-blind, placebo-controlled trial of Probiotics To Eliminate COVID-19 Transmission in Exposed Household Contacts (PROTECT-EHC): a clinical trial protocol. <i>BMJ Open</i> , <b>2021</b> , 11, e047069	3	8
515	Review of Pharmacotherapy Tried for Management of the Coronavirus Disease-19. <b>2021</b> , 53, 137-143		2
514	Can the COVID-19 Pandemic Disrupt the Current Drug Development Practices?. <b>2021</b> , 22,		2
513	A human-airway-on-a-chip for the rapid identification of candidate antiviral therapeutics and prophylactics. <b>2021</b> , 5, 815-829		62
512	Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: An open-label randomized trial. <b>2021</b> , 106, 314-322		22
511	Hydroxychloroquine as prophylaxis when treating patients with coronavirus disease 2019 □ Perception of frontline health care workers in South India. 73, 141-146		
510	The Role of Nutrition in COVID-19 Susceptibility and Severity of Disease: A Systematic Review. <b>2021</b> , 151, 1854-1878		24
509	Perspective: the nose and the stomach play a critical role in the NZACE2-Pfari* (modified ACE2) drug treatment project of SARS-CoV-2 infection. <b>2021</b> , 17, 553-560		4
508	Patients with COVID-19: in the dark-NETs of neutrophils. <b>2021</b> , 28, 3125-3139		61
507	COVID-19: breaking down a global health crisis. <b>2021</b> , 20, 35		43
506	Therapeutic Potential of Exploiting Autophagy Cascade Against Coronavirus Infection. <b>2021</b> , 12, 675419		13
505	Strategy, Progress, and Challenges of Drug Repurposing for Efficient Antiviral Discovery. <b>2021</b> , 12, 660710		6
504	Chemoprophylaxis trial designs in epidemics: insights from a systematic review of COVID-19 study registrations. <b>2021</b> , 22, 370		0
503	Therapeutic strategies to fight COVID-19: Which is the status artis?. <b>2021</b> ,		12
502	How COVID-19 has fundamentally changed clinical research in global health. <b>2021</b> , 9, e711-e720		20
501	Clinical Features and Maternal-fetal Results of Pregnant Women in COVID-19 Times. <b>2021</b> , 43, 384-394		1

500	Quantifying the relationship between SARS-CoV-2 viral load and infectiousness.	4
499	Efficacy of GC-376 against SARS-CoV-2 virus infection in the K18 hACE2 transgenic mouse model. <b>2021</b> , 11, 9609	18
498	Discovery of Cyclic Peptide Ligands to the SARS-CoV-2 Spike Protein Using mRNA Display. <b>2021</b> , 7, 1001-1008	8
497	Pharmacovigilance-based drug repurposing: The search for inverse signals via OpenVigil identifies putative drugs against viral respiratory infections. <b>2021</b> , 87, 4421-4431	4
496	A CRISPR/Cas9 genetically engineered organoid biobank reveals essential host factors for coronaviruses.	2
495	Summary of adverse drug events for hydroxychloroquine, azithromycin, and chloroquine during the COVID-19 pandemic. <b>2021</b> , 61, 293-298	4
494	Tocilizumab as treatment for COVID-19: A systematic review and meta-analysis. <b>2021</b> , 11, 95-109	1
493	Improving the Outcomes of Immunocompromised Patients With Coronavirus Disease 2019. <b>2021</b> , 73, e1397-e1401	17
492	Modeling SARS-CoV-2 and Influenza Infections and Antiviral Treatments in Human Lung Epithelial Tissue Equivalents. <b>2021</b> ,	3
491	Mortality, viral clearance, and other clinical outcomes of hydroxychloroquine in COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials. <b>2021</b> , 14, 1101-1112	4
490	SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19.	1
489	Risk of COVID-19 infection in patients with rheumatic disease taking disease-modifying anti-rheumatic drugs. <b>2021</b> , 40, 4309-4315	2
488	Efficacy and safety of Xiyanping injection in the treatment of COVID-19: A multicenter, prospective, open-label and randomized controlled trial. <b>2021</b> , 35, 4401-4410	10
487	Exploring insights of hydroxychloroquine, a controversial drug in Covid-19: An update. <b>2021</b> , 151, 112106	3
486	Severe COVID-19 in pediatric age: an update on the role of the anti-rheumatic agents. <b>2021</b> , 19, 68	2
485	Clinical Management of COVID-19: A Review of Pharmacological Treatment Options. <b>2021</b> , 14,	10
484	Hydroxychloroquine and mortality in COVID-19 patients: a systematic review and a meta-analysis of observational studies and randomized controlled trials. <b>2021</b> , 115, 456-466	5
483	HIV and COVID-19: Lessons From HIV and STI Harm Reduction Strategies. <b>2021</b> , 18, 261-270	2

482	Impact of Prophylactic Hydroxychloroquine on People at High Risk of COVID-19: A Systematic Review and Meta-Analysis. <b>2021</b> , 10,	3
481	International Changes in COVID-19 Clinical Trajectories Across 315 Hospitals and 6 Countries: Retrospective Cohort Study. <b>2021</b> , 23, e31400	2
480	A Study to Assess the Knowledge and Perception of Practicing Dental Professionals Toward COVID-19 in Lucknow City. <b>2021</b> , 1-11	1
479	Models and Mechanisms for COVID-19 Research. <b>2021</b> , 14,	1
478	Zinc supplementation as an adjunct therapy for COVID-19: Challenges and opportunities. <b>2021</b> , 87, 3737-3746	10
477	Chronic hydroxychloroquine therapy and COVID-19 outcomes: A retrospective case-control analysis. <b>2021</b> , 84, 1769-1772	
476	. <b>2021</b> , 13, 1S63-1S67	
475	Insights into SARS-CoV-2 evolution, potential antivirals, and vaccines. <b>2021</b> , 558, 1-12	9
474	Efficacy and safety of hydroxychloroquine as pre-and post-exposure prophylaxis and treatment of COVID-19. Systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials.	
473	[SARS-CoV-2 infection: Available data on 15th April 2021]. <b>2021</b> , 38, 616-625	
472	Evidence-based approach to early outpatient treatment of SARS-CoV-2 (COVID-19) infection. <b>2021</b> , 34, 464-468	1
471	Public health relevant consequences of the COVID-19 pandemic on malaria in sub-Saharan Africa: A scoping review.	0
470	COVID-19 and cytokine storm syndrome: are there lessons from macrophage activation syndrome?. <b>2021</b> , 232, 1-12	22
469	Friends or Foes? An Update on Retinal Toxicities of Systemic Medications. <b>2021</b> , 52, 302-306	
468	Adverse Effects Associated With the Use of Antimalarials During The COVID-19 Pandemic in a Tertiary Care Center in Mexico City. <b>2021</b> , 12, 668678	2
467	International Changes in COVID-19 Clinical Trajectories Across 315 Hospitals and 6 Countries: a 4CE Consortium Study (Preprint).	
466	Rationale for a New Outpatient Drug Therapy Algorithm in COVID-19 Patients Based on the Principle of «Multi-hit» Approach. <b>2021</b> , 66, 49-61	0
465	AI-based language models powering drug discovery and development. <b>2021</b> , 26, 2593-2607	6

464	Efficacy and safety of hydroxychloroquine/chloroquine against SARS-CoV-2 infection: A systematic review and meta-analysis. <b>2021</b> , 27, 882-889	10
463	Sex-Related Overactivation of NLRP3 Inflammasome Increases Lethality of the Male COVID-19 Patients. <b>2021</b> , 8, 671363	6
462	COVID-19 in Solid Organ Transplant Recipients in Spain Throughout 2020: Catching the Wave?. <b>2021</b> , 105, 2146-2155	5
461	SARS-CoV-2 Antiviral Therapy. <b>2021</b> , e0010921	12
460	Immunomodulation as a Potent COVID-19 Pharmacotherapy: Past, Present and Future. <b>2021</b> , 14, 3419-3428	4
459	Impact of COVID-19 on a brain damage unit. <b>2021</b> , 15, 102163	
458	A tale of two diseases: Sarcoidosis, COVID-19 and new therapeutic options with dual RAS inhibition and tetanus-diphtheria vaccine. <b>2021</b> , 152, 110619	0
457	Prophylaxis Against COVID-19 With Hydroxychloroquine and Chloroquine: Comment on the Article by Putman et al. <b>2021</b> , 73, 1765-1767	
456	Antiviral Activity of Influenza A Virus Defective Interfering Particles against SARS-CoV-2 Replication In Vitro through Stimulation of Innate Immunity. <b>2021</b> , 10,	9
455	Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19. <b>2021</b> , 76, 285-295	3
454	New perspective towards therapeutic regimen against SARS-CoV-2 infection. <b>2021</b> , 14, 852-862	0
453	Hydroxychloroquine as a primary prophylactic agent against SARS-CoV-2 infection: A cohort study. <b>2021</b> , 108, 370-376	3
452	Pharmacological interventions for COVID-19: a systematic review of observational studies and clinical trials. <b>2021</b> , 19, 1219-1244	3
451	Efficacy of Different Types of Therapy for COVID-19: A Comprehensive Review. <b>2021</b> , 11,	6
450	Analysis of COVID-19 Guideline Quality and Change of Recommendations: A Systematic Review. <b>2021</b> , 2021, 1-22	0
449	Maternal exposure to hydroxychloroquine and birth defects. <b>2021</b> , 113, 1245-1256	0
448	Concerning Pathophysiology and Justifying Clinical Trials. <b>2021</b> , 134, e439	0
447	Favipiravir and Hydroxychloroquine Combination Therapy in Patients with Moderate to Severe COVID-19 (FACCT Trial): An Open-Label, Multicenter, Randomized, Controlled Trial. <b>2021</b> , 10, 2291-2307	7

446	Recent updates on the possible reasons for the low incidence and morbidity of COVID-19 cases in Africa. <b>2021</b> , 45, 133	3
445	Rilpivirine inhibits SARS-CoV-2 protein targets: A potential multi-target drug. <b>2021</b> , 14, 1454-1460	1
444	Utilization of drugs with reports on potential efficacy or harm on COVID-19 before, during, and after the first pandemic wave. <b>2021</b> , 30, 1493-1503	2
443	Accelerating vaccine trial conduct in a pandemic with a hot spot-based inclusion strategy using trial and epidemic simulation. <b>2021</b> , 14, 2391-2398	1
442	Possible role of exogenous melatonin in preventing more serious COVID-19 infection in patients with type 2 diabetes mellitus. <b>2021</b> , 67Suppl 1, 18-21	1
441	Comprehensive Consensus Analysis of SARS-CoV-2 Drug Repurposing Campaigns. <b>2021</b> , 61, 3771-3788	6
440	Sales of antibiotics and hydroxychloroquine in India during the COVID-19 epidemic: An interrupted time series analysis. <b>2021</b> , 18, e1003682	29
439	Lessons learnt from hydroxychloroquine/azithromycin in treatment of COVID-19. <b>2021</b> ,	3
438	Media coverage of COVID-19 health information in India: a content analysis. <b>2021</b> ,	0
437	Outpatient Management of COVID-19 Disease: A Holistic Patient-Centered Proposal Based on the Greek Experience. <b>2021</b> , 11,	1
436	Targeting autophagy in disease: established and new strategies. <b>2021</b> , 1-23	13
435	The Conundrum of Low COVID-19 Mortality Burden in sub-Saharan Africa: Myth or Reality?. <b>2021</b> , 9, 433-443	22
434	Hydroxychloroquine plus azithromycin early treatment of mild COVID-19 in an outpatient setting: a randomized, double-blinded, placebo-controlled clinical trial evaluating viral clearance. <b>2021</b> , 58, 106428	2
433	Role of potential COVID-19 immune system associated genes and the potential pathways linkage with type-2 diabetes. <b>2021</b> ,	3
432	Public health-relevant consequences of the COVID-19 pandemic on malaria in sub-Saharan Africa: a scoping review. <b>2021</b> , 20, 339	11
431	Updates on Hydroxychloroquine in Prevention and Treatment of COVID-19. <b>2021</b> ,	3
430	Clinical Characteristics of Confirmed Cases of COVID-19 Admitted at Al Nahdha Hospital, Oman: A Cross-Sectional Descriptive Study. <i>Cureus</i> , <b>2021</b> , 13, e17343	1.2 1
429	Discovery of Antiviral Cyclic Peptides Targeting the Main Protease of SARS-CoV-2 via mRNA Display.	



428	The Need for a US National Clinical Trial Infrastructure in a Public Health Crisis. <b>2021</b> , 2, e213223	2
427	Model-Informed Repurposing of Medicines for SARS-CoV-2: Extrapolation of Antiviral Activity and Dose Rationale for Paediatric Patients. <b>2021</b> , 13,	2
426	Virgin coconut oil is effective in lowering C-reactive protein levels among suspect and probable cases of COVID-19. <b>2021</b> , 83, 104557	3
425	Electrophysiological and Proarrhythmic Effects of Hydroxychloroquine Challenge in Guinea-Pig Hearts. <b>2021</b> , 4, 1639-1653	0
424	Efficacy and safety of hydroxychloroquine as pre-and post-exposure prophylaxis and treatment of COVID-19: A systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials. <b>2021</b> , 2, 100062	9
423	Identification of cell lines CL-14, CL-40 and CAL-51 as suitable models for SARS-CoV-2 infection studies. <i>PLoS ONE</i> , <b>2021</b> , 16, e0255622	3-7 7
422	Progress and pitfalls of a year of drug repurposing screens against COVID-19. <b>2021</b> , 49, 183-193	9
421	Medicinal chemistry strategies towards the development of effective SARS-CoV-2 inhibitors. <b>2021</b> ,	5
420	Current status of therapeutic alternatives for COVID-19: A narrative review.. <b>2021</b> , 29, 312-327	2
419	The association between malaria prevalence and COVID-19 mortality. <b>2021</b> , 21, 975	2
418	A CRISPR/Cas9 genetically engineered organoid biobank reveals essential host factors for coronaviruses. <b>2021</b> , 12, 5498	15
417	Clinical trials with antiviral drugs against COVID-19: some progress and many shattered hopes. <b>2021</b> , 23, 6364-6376	4
416	COVID-19 Therapeutics for Low- and Middle-Income Countries: A Review of Candidate Agents with Potential for Near-Term Use and Impact. <b>2021</b> , 105, 584-595	3
415	Characteristics of US Patients and Prescribers Using Hydroxychloroquine During the COVID-19 Pandemic. <b>2021</b> , 36, 3918-3921	
414	Changes in dispensing of medicines proposed for re-purposing in the first year of the COVID-19 pandemic in Australia.	
413	Endocytosis and Transcytosis of SARS-CoV-2 Across the Intestinal Epithelium and Other Tissue Barriers. <b>2021</b> , 12, 636966	6
412	Tetavalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations. <b>2021</b> , 433, 167177	10
411	A hitchhiker's guide through the COVID-19 galaxy. <b>2021</b> , 232, 108849	0

410	Quantifying the relationship between SARS-CoV-2 viral load and infectiousness. <b>2021</b> , 10,	20
409	Clinical Characteristics and Outcome of COVID-19 in Turkish Hematological Malignancy Patients. <b>2021</b> ,	0
408	Low dose hydroxychloroquine prophylaxis for COVID-19 [A] prospective study.	
407	The future is now: our experience starting a remote clinical trial during the beginning of the COVID-19 pandemic. <b>2021</b> , 22, 603	1
406	Treatment of moderate to severe respiratory COVID-19: a cost-utility analysis. <b>2021</b> , 11, 17787	5
405	Hydroxychloroquine induces oxidative DNA damage and mutation in mammalian cells. <b>2021</b> , 106, 103180	1
404	Evaluation of the prophylactic effect of hydroxychloroquine on people in close-contact with patients with COVID-19. <b>2021</b> , 70, 102069	0
403	Design of the Healthcare Worker Exposure Response and Outcomes (HERO) research platform. <b>2021</b> , 109, 106525	0
402	Efficacy of a Nasal Spray Containing Iota-Carrageenan in the Postexposure Prophylaxis of COVID-19 in Hospital Personnel Dedicated to Patients Care with COVID-19 Disease. <b>2021</b> , 14, 6277-6286	14
401	Abstracts for reports of randomised trials of COVID-19 interventions had low quality and high spin. <b>2021</b> , 107-120	4
400	Synthesis and pharmacological evaluation of chloroquine derivatives bearing long aminated side chains as antiviral and anti-inflammatory agents. <b>2021</b> , 116, 105346	0
399	Clinical trials in COVID-19 management & prevention: A meta-epidemiological study examining methodological quality. <b>2021</b> , 139, 68-79	3
398	COVID-19 and Ivermectin: Potential threats associated with human use. <b>2021</b> , 1243, 130808	2
397	Medicines for the new coronavirus in the view of Classical Systemic Homeopathy. <b>2021</b> , 45, 101482	2
396	Recent advances in drug repurposing using machine learning. <b>2021</b> , 65, 74-84	5
395	Assessing the quality of randomization methods in randomized control trials. <b>2021</b> , 9, 100570	
394	Drugs for the Treatment of COVID-19. <b>2021</b> , 193-204	
393	Infectious disease immunotherapies [An update: Revisiting an age-old adage in times of COVID-19. <b>2021</b> , 23, 10	

392	Remdesivir - Current evidence & perspective in management of COVID-19 infection. <b>2021</b> , 10, 1808-1813	2
391	SARS-CoV-2 Cellular Infection and Therapeutic Opportunities: Lessons Learned from Ebola Virus. <b>2021</b> , 11,	
390	Utilisation, Availability and Price Changes of Medicines and Protection Equipment for COVID-19 Among Selected Regions in India: Findings and Implications. <b>2020</b> , 11, 582154	17
389	Interpreting the impact of hydroxychloroquine prophylaxis on SARS-CoV-2 infection. <b>2021</b> , 153, 564-565	
388	Experimental Pharmacotherapy for COVID-19: The Latest Advances. <b>2021</b> , 13, 1-13	14
387	Safety and Efficacy of Chloroquine/Hydroxychloroquine in SARS-CoV-2 Infection. <b>2021</b> , 33, 1718-1722	1
386	COVID-19 treatment options: a difficult journey between failed attempts and experimental drugs. <b>2021</b> , 16, 281-308	21
385	The efficacy and safety of hydroxychloroquine for COVID-19 prophylaxis: A systematic review and meta-analysis of randomized trials. <i>PLoS ONE</i> , <b>2021</b> , 16, e0244778	3.7 25
384	Hydroxychloroquine and chloroquine for treatment of coronavirus disease 19 (COVID-19): a systematic review and meta-analysis of randomized and non-randomized controlled trials. <b>2021</b> , 13, 202-212	4
383	Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study. <b>2021</b> , 21, 72	19
382	Acute severe respiratory syndrome coronavirus-2 treatment overview for pediatrics. <b>2021</b> , 33, 129-135	1
381	COVID-19 Transmission, Current Treatment, and Future Therapeutic Strategies. <b>2021</b> , 18, 754-771	58
380	Impact of repurposed drugs on the symptomatic COVID-19 patients. <b>2021</b> , 14, 24-38	3
379	Case Management of COVID-19 (Secondary Version). <b>2021</b> , 4, 191-197	5
378	Error in References Section. <b>2021</b> , 4, e2036103	
377	Response to a massive SARS-CoV-2 infection in a nursing home transformed into a caring center. <b>2021</b> , 33, 443-450	2
376	Reply to letter to editor by McCullough. <b>2021</b> , 53, 335-336	
375	Hydroxychloroquine and COVID-19: a Rheumatologist's Take on the Lessons Learned. <b>2021</b> , 21, 5	4

374	Prevalence of COVID-19 in patients with rheumatoid arthritis (RA) already treated with hydroxychloroquine (HCQ) compared with HCQ-naive patients with RA: a multicentre cross-sectional study. <b>2021</b> ,	
373	COVID-19: What Do Rheumatologists Need to Know?. <b>2021</b> , 23, 5	3
372	Looking back, moving forward. <b>2021</b> , 167-216	
371	Bioinformatics resources facilitate understanding and harnessing clinical research of SARS-CoV-2. <b>2021</b> , 22, 714-725	12
370	Hydroxychloroquine in COVID-19: therapeutic promises, current status, and environmental implications. <b>2021</b> , 28, 40431-40444	13
369	The journey of antimalarial drugs against SARS-CoV-2: Review article. <b>2021</b> , 24, 100604	17
368	Drug repurposing screens reveal FDA approved drugs active against SARS-Cov-2.	1
367	Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 In Vitro and SARS-CoV In Vivo. <b>2020</b> , 94,	1
366	Progresses in clinical studies on antiviral therapies for COVID-19-Experience and lessons in design of clinical trials. <b>2020</b> , 4, 263-274	3
365	The association of treatment with hydroxychloroquine and hospital mortality in COVID-19 patients. <b>2020</b> , 15, 1501-1506	18
364	COVID-19: Antiviral Agents, Antibody Development and Traditional Chinese Medicine. <b>2020</b> , 35, 685-698	6
363	Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses. <b>2020</b> , 53, 100721	44
362	High-profile coronavirus retractions raise concerns about data oversight. <b>2020</b> , 582, 160	38
361	Therapeutics for COVID-19: established and in development. <b>2020</b> , 41, 217	2
360	Natural history of COVID-19 and therapeutic options. <b>2020</b> , 16, 1159-1184	41
359	Risk of depression, suicide and psychosis with hydroxychloroquine treatment for rheumatoid arthritis: a multinational network cohort study. <b>2021</b> , 60, 3222-3234	10
358	Prostate cancer: a risk factor for COVID-19 in males?: A protocol for systematic review and meta analysis. <b>2020</b> , 99, e22591	4
357	Hydroxychloroquine and COVID-19: Lack of Efficacy and the Social Construction of Plausibility. <b>2020</b> , 27, e573-e583	3

356	COVID-19 Therapeutics for Solid Organ Transplant Recipients; 6 Months Into the Pandemic: Where Are We Now?. <b>2021</b> , 105, 56-60	13
355	Organ Donation and Transplantation During the COVID-19 Pandemic: A Summary of the Spanish Experience. <b>2021</b> , 105, 29-36	23
354	Solid Organ Transplantation in the Era of COVID-19: Lessons from France. <b>2021</b> , 105, 61-66	13
353	Human organ chip-enabled pipeline to rapidly repurpose therapeutics during viral pandemics.	39
352	Easing COVID-19 lockdown measures while protecting the older restricts the deaths to the level of the full lockdown.	3
351	THE TIME COURSE OF THERAPEUTIC INTERVENTIONS FOR COVID-19.	2
350	COVID-19 related mortality and spread of disease in long-term care: a living systematic review of emerging evidence.	19
349	Drug repurposing screens reveal FDA approved drugs active against SARS-Cov-2.	35
348	Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection.	4
347	Plasma IL-6 Levels following Corticosteroid Therapy as an Indicator of ICU Length of Stay in Critically ill COVID-19 Patients.	4
346	Treatment Response to Hydroxychloroquine and Antibiotics for mild to moderate COVID-19: a retrospective cohort study from South Korea.	5
345	Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations.	1
344	Discovery of clinically approved drugs capable of inhibiting SARS-CoV-2 in vitro infection using a phenotypic screening strategy and network-analysis to predict their potential to treat covid-19.	8
343	COVID-19 scenarios for the United States.	3
342	Risk of depression, suicidal ideation, suicide and psychosis with hydroxychloroquine treatment for rheumatoid arthritis: a multi-national network cohort study.	0
341	Inhibitors of L-type calcium channels show therapeutic potential for treating SARS-CoV-2 infections by preventing virus entry and spread.	16
340	Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2.	8
339	Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: A multi-center observational study.	7

338	The S1/S2 boundary of SARS-CoV-2 spike protein modulates cell entry pathways and transmission.	21
337	COVID-19 and Multisystem Inflammatory Syndrome in Latin American children: a multinational study.	2
336	Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial. <b>2020,</b>	17
335	A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent in vitro. <b>2020,</b>	4
334	Brief communication: A meta-analysis of randomized trials of hydroxychloroquine for the prevention of COVID-19.	4
333	Randomized Controlled Trials of Early Ambulatory Hydroxychloroquine in the Prevention of COVID-19 Infection, Hospitalization, and Death: Meta-Analysis.	13
332	COVID-19 neutralizing antibodies predict disease severity and survival. <b>2020,</b>	10
331	Melatonin is significantly associated with survival of intubated COVID-19 patients. <b>2020,</b>	23
330	Could nutrition modulate COVID-19 susceptibility and severity of disease? A systematic review.	8
329	Role of ivermectin in the prevention of COVID-19 infection among healthcare workers in India: A matched case-control study.	9
328	Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations. <b>2020,</b>	8
327	Low dose hydroxychloroquine is associated with lower mortality in COVID-19: a meta-analysis of 26 studies and 44,521 patients.	2
326	Effective post-exposure prophylaxis of Covid-19 is associated with use of hydroxychloroquine: Prospective re-analysis of a public dataset incorporating novel data.	2
325	THE THERAPEUTIC POTENTIAL OF IVERMECTIN FOR COVID-19: A SYSTEMATIC REVIEW OF MECHANISMS AND EVIDENCE.	4
324	A two-arm, randomized, controlled, multi-centric, open-label Phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19.	3
323	Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine and Pyronaridine: In vitro Activity Against SARS-CoV-2 and Potential Mechanisms. <b>2020,</b>	4
322	Credible learning of hydroxychloroquine and dexamethasone effects on COVID-19 mortality outside of randomized trials. <b>2020,</b>	1
321	Potent anti-SARS-CoV-2 activity by gallinamide A and analogues via inhibition of cathepsin L. <b>2020,</b>	9

320	Open drug discovery of anti-virals critical for Canada's pandemic strategy. <b>2020</b> , 5, 1019-1036		1
319	Primum non nocere - Are chloroquine and hydroxychloroquine safe prophylactic/treatment options for SARS-CoV-2 (covid-19)?. <b>2020</b> , 54, 68		4
318	Hydroxychloroquine prophylaxis and treatment is ineffective in macaque and hamster SARS-CoV-2 disease models. <b>2020</b> , 5,		20
317	Malaria and COVID-19: unmasking their ties. <b>2020</b> , 19, 457		30
316	The immune system view of the coronavirus SARS-CoV-2. <b>2020</b> , 15, 30		10
315	Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis. <b>2020</b> , 22, 290		17
314	SARS-CoV-2 Infection and COVID-19 in 5 Patients in Ecuador After Prior Treatment with Hydroxychloroquine for Systemic Lupus Erythematosus. <b>2020</b> , 21, e927304		4
313	The worldwide clinical trial research response to the COVID-19 pandemic - the first 100 days. <i>F1000Research</i> , <b>2020</b> , 9, 1193	3.6	28
312	The worldwide clinical trial research response to the COVID-19 pandemic - the first 100 days. <i>F1000Research</i> , <b>2020</b> , 9, 1193	3.6	22
311	Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis. <b>2020</b> , 17, e1003501		78
310	Lack of protective effect of chloroquine derivatives on COVID-19 disease in a Spanish sample of chronically treated patients. <i>PLoS ONE</i> , <b>2020</b> , 15, e0243598	3.7	1
309	Hydroxychloroquine in rheumatic autoimmune disorders and beyond. <b>2020</b> , 12, e12476		29
308	COVID-19: molecular targets, drug repurposing and new avenues for drug discovery. <b>2020</b> , 115, e200254		11
307	Chronic heart diseases as the most prevalent comorbidities among deaths by COVID-19 in Brazil. <b>2020</b> , 62, e45		15
306	Risk of COVID-19 infection among lupus erythematosus patients and rheumatoid arthritis patients: a retrospective study in Hubei, China. <b>2020</b> , 30, 751-753		3
305	[Combination therapy at an early stage of the novel coronavirus infection (COVID-19). Case series and design of the clinical trial "Bromhexine and Spironolactone for Coronavirus Infection requiring hospitalization (BISCUIT)". <b>2020</b> , 60, 4-15		7
304	COVID-19 and children. <b>2020</b> , 30, 609-628		6
303	The Landscape of Emerging Randomized Clinical Trial Evidence for COVID-19 Disease Stages: A Systematic Review of Global Trial Registries. <b>2020</b> , 13, 4577-4587		6

302	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications. <b>2020</b> , 13, 4673-4695	20
301	COVID-19: A Therapeutic Approach Based on Pathophysiological Staging. <b>2020</b> , 14, 32-37	0
300	Pharmacological treatment of COVID-19: an update.	1
299	A Case of Breakthrough COVID-19 during Hydroxychloroquine Maintenance. <b>2020</b> , 35, e231	4
298	Hydroxychloroquine as a Chemoprophylactic Agent for COVID-19: A Clinico-Pharmacological Review. <b>2020</b> , 11, 593099	4
297	Hydroxychloroquine in COVID-19 Patients: Pros and Cons. <b>2020</b> , 11, 597985	13
296	COVID-19-Associated Hyper-Fibrinolysis: Mechanism and Implementations. <b>2020</b> , 11, 596057	7
295	Rapid Assessment of Price Instability and Paucity of Medicines and Protection for COVID-19 Across Asia: Findings and Public Health Implications for the Future. <b>2020</b> , 8, 585832	32
294	The Current Status of Drug Repositioning and Vaccine Developments for the COVID-19 Pandemic. <b>2020</b> , 21,	25
293	COVID-19: A Global Challenge with Old History, Epidemiology and Progress So Far. <b>2020</b> , 26,	94
292	Evaluation of drugs for potential repurposing against COVID-19 using a tier-based scoring system. <b>2020</b> , 25, 223-231	6
291	COVID-19 in China: From epidemiology to treatment (Review). <b>2020</b> , 20, 223	2
290	Early Hydroxychloroquine Administration for Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Eradication. <b>2020</b> , 52, 396-402	9
289	Safety of hydroxychloroquine in healthcare workers for COVID-19 prophylaxis. <b>2021</b> , 153, 219-226	1
288	Therapeutic status of hydroxychloroquine in COVID-19: A review. <b>2020</b> , 36, S160-S165	4
287	Hydroxychloroquine in the Treatment of COVID-19: A Multicenter Randomized Controlled Study. <b>2020</b> , 103, 1635-1639	77
286	How Do We Combat Bogus Medicines in the Age of the COVID-19 Pandemic?. <b>2020</b> , 103, 1360-1363	8
285	Pragmatic Recommendations for Therapeutics of Hospitalized COVID-19 Patients in Low- and Middle-Income Countries. <b>2020</b> ,	3



284	The Role of Hydroxychloroquine in COVID-19 Treatment: A Systematic Review and Meta-Analysis. <b>2020</b> , 49,	7
283	Hydroxychloroquine and Coronavirus Disease 2019: A Systematic Review of a Scientific Failure. <b>2020</b> , 11,	6
282	Immunotherapy for ANCA-associated vasculitis during the COVID-19 pandemic. <b>2020</b> , 7, S121-S128	5
281	Cardiotoxicity induced by the combination therapy of chloroquine and azithromycin in human embryonic stem cell-derived cardiomyocytes. <b>2020</b> , 53, 545-550	1
280	Chest computed tomography in the diagnosis of COVID-19 in patients with false negative RT-PCR. <b>2021</b> , 19, eAO6363	0
279	COVID-19 treatments sold online without prescription requirements in the United States. <b>2021</b> ,	1
278	Ethical Considerations of Hydroxychloroquine During the COVID-19 Pandemic. <b>2021</b> , 68, 7-8	
277	Impact of Hydroxychloroquine Treatment of COVID-19 on Cardiac Conduction: The Beat Goes On. <b>2021</b> , 1, 458-464	
276	HeberNasvac, a Therapeutic Vaccine for Chronic Hepatitis B, Stimulates Local and Systemic Markers of Innate Immunity: Potential Use in SARS-CoV-2 Postexposure Prophylaxis. <b>2021</b> , 11, 59-70	1
275	PABPC4 Broadly Inhibits Coronavirus Replication by Degrading Nucleocapsid Protein through Selective Autophagy. <b>2021</b> , 9, e0090821	5
274	Pre-Exposure Prophylaxis with Hydroxychloroquine Does Not Prevent COVID-19 nor Virus Related Venous Thromboembolism. <b>2021</b> , 13,	0
273	What went wrong: A reckoning of Canada's contributions to evidence-based medicine through clinical trials during the COVID-19 pandemic.	1
272	Harnessing autophagy to fight SARS-CoV-2: An update in view of recent drug development efforts. <b>2021</b> ,	2
271	COVID-19 Therapy: the Role of Antirheumatic Drugs. <b>2021</b> , 66, 83-89	
270	Pivoting to a Remote-Learning Summer Student Program during the COVID-19 Pandemic.. <b>2021</b> , 2, 521-534	0
269	Clinical drug therapies and biologicals currently used or in clinical trial to treat COVID-19. <b>2021</b> , 144, 112276	3
268	COVID-19 Infection and Children: A Comprehensive Review. <b>2020</b> , 11, 157	0
267	Hydroxychloroquine as pre-exposure prophylaxis against COVID-19 in health-care workers: A single-center experience. <b>2020</b> ,	

- 266 Hydroxychloroquine and mortality risk of patients with COVID-19: a systematic review and meta-analysis of human comparative studies.
- 265 Characterization of cells susceptible to SARS-COV-2 and methods for detection of neutralizing antibody by focus forming assay. 3
- 264 Coronaviral Infection (COVID-19) in Children (Situation on June 2020). **2020**, 17, 162-178 3
- 263 Preventing disease after exposure to COVID-19 using hydroxychloroquine: A summary of a protocol for exploratory re-analysis of age and time-nuanced effects. 2
- 262 Review of current clinical management guidelines for COVID-19 with special reference to India. **2020**, 14, 171-176 3
- 261 COVID-19 Pandemic in WomenRheumatologistĒ Perspective. **2020**, 5, 250-255
- 260 Treatment of Moderate to Severe Respiratory COVID-19Ā Cost-Utility Analysis.
- 259 COVID-19 e suas correlaĒs com as doenĒas reumĒicas em crianĒs. **2020**, 36-42
- 258 Hydroxychloroquine prophylaxis for SARS-CoV-2 infection among healthcare workers. **2020**, 152, 119-120 1
- 257 Panorama de pesquisas com seres humanos sobre covid-19 no Brasil. **2020**, 28, 655-663
- 256 The aging whole blood transcriptome reveals a potential role of FASLG in COVID-19.
- 255 Progress in the risk assessment of hydroxychloroquine in frail elderly people. **2021**, 4, 53-57
- 254 Discovery of Cyclic Peptide Ligands to the SARS-CoV-2 Spike Protein using mRNA Display.
- 253 Waiting for Godot: A cross sectional survey based analysis of the hydroxychloroquine prophylaxis strategy against COVID-19 in India. **2020**, 9, 1888
- 252 Current evidence for COVID-19 therapies: a systematic literature review.
- 251 Detailed disease progression of 213 patients hospitalized with Covid-19 in the Czech Republic: An exploratory analysis.
- 250 Potentials of Interferons and Hydroxychloroquine for the Prophylaxis and Early Treatment of COVID-19. **2020**, 2, 333-340 0
- 249 Weathering the storm: COVID-19 infection in patients with hematological malignancies. **2020**, 21, 921-939 2

248	A Rare Presentation of Cerebrovascular Accident in a COVID-19 Patient: A Case Report. <i>Cureus</i> , <b>2020</b> , 12, e12287	1.2
247	Lessons Learned From Conducting Internet-Based Randomized Clinical Trials During a Global Pandemic. <b>2021</b> , 8, ofaa602	3
246	COVID-19: the billion nation story. <b>2020</b> ,	
245	Reply to Neves. <b>2021</b> , 73, e1772-e1774	2
244	From quarantine room: Physician perspective. <b>2020</b> , 9, 5092-5102	2
243	COVID-19 pandemic: Case studies and perspectives. <b>2020</b> , 42, 291-297	1
242	Treatment of COVID19 with antimalarial medicines: clinical pharmacology analysis. <b>2020</b> , 22, 164-174	
241	Management of COVID-19: A brief overview of the various treatment strategies. <b>2020</b> , 3, 233	1
240	Critical Care for COVID-19 Affected Patients: Updated Position Statement of the Indian Society of Critical Care Medicine. <b>2020</b> , 24, S225-S230	2
239	Hydroxychloroquine Use in Patients With COVID-19: A Brief Perspective on Current Clinical Trials. <b>2020</b> , 20, 350-357	
238	Fever in the returning traveller : dual infection with SARS-CoV-2 and Plasmodium falciparum malaria. <b>2020</b> , 2, 105-108	
237	Authors' response. <b>2020</b> , 152, 120	
236	Recruitment for Remote Decentralized Studies in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , <b>2021</b> ,	5-3 1
235	Systematic review and meta-analysis of the safety of chloroquine and hydroxychloroquine from randomized controlled trials on malarial and non-malarial conditions. <b>2021</b> , 10, 294	0
234	Ocular manifestations in COVID-19 patients: A systematic review and meta-analysis. <b>2021</b> , 44, 102191	4
233	Identification and Development of Therapeutics for COVID-19. <b>2021</b> , e0023321	5
232	Aging whole blood transcriptome reveals candidate genes for SARS-CoV-2-related vascular and immune alterations. <b>2021</b> , 1	2
231	Potent Anti-SARS-CoV-2 Activity by the Natural Product Gallinamide A and Analogues via Inhibition of Cathepsin L. <b>2021</b> ,	4

- 230 Post-exposure Lopinavir-Ritonavir Prophylaxis versus Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster Randomized Trial. **2021**, 42, 101188 1
- 229 Methodological Rigor in COVID-19 Clinical Research [A Systematic Review and Case-Control Analysis]. 1
- 228 Top ten tips for perfect corona-2 prophylaxis. **2020**, 10, 55-57
- 227 Psychiatric side effects induced by chloroquine and hydroxychloroquine: a systematic review of case reports and population studies. 1
- 226 Low zinc levels at clinical admission associates with poor outcomes in COVID-19. 1
- 225 What should we prepare for the next coronavirus disease 2019 outbreak? A survey on the opinions of infectious diseases specialists in South Korea. **2020**, 35, 1270-1278 2
- 224 The papain-like protease of coronaviruses cleaves ULK1 to disrupt host autophagy.
- 223 Core Concept: The pandemic is prompting widespread use-and misuse-of real-world data. **2020**, 117, 27754-27758 3
- 222 Editorial: The battle for survival between severe acute respiratory syndrome coronavirus 2 and human beings. **2020**, 15, 325-327
- 221 Change of opinion on the use of hydroxychloroquine for COVID-19 treatment and prevention. **2020**, 90-91
- 220 Lack of protective effect of chloroquine derivatives on COVID-19 disease in a Spanish sample of chronically treated patients.
- 219 Personalized Prescription of ACEI/ARBs for Hypertensive COVID-19 Patients.
- 218 Clinical Trials in COVID-19 Management & Prevention: A Meta-epidemiological Study examining methodological quality.
- 217 Investigational Drugs for the COVID 19 Pandemic [A Concise Review. **2020**, 26, S36-S48
- 216 The Role of Hydroxychloroquine in COVID-19 Treatment: A Systematic Review and Meta-Analysis. **2020**, 1
- 215 Hydroxicloroquine for Pre-Exposure Prophylaxis for SARS-COV-2.
- 214 Therapeutic strategies against COVID-19. **2020**, 91, e2020038 2
- 213 Cardiovascular Complications of COVID-19 and Associated Concerns: A Review. **2021**, 37, 9-17 1

212	It is time to consider an anti-inflammatory therapy based on the pathophysiology of COVID-19 infection during the right time window?. <b>2021</b> , 17, 546-550	
211	Medication use during COVID-19: Review of recent evidence. <b>2021</b> , 67, 171-179	1
210	. <b>2021</b> , 67, e69-e78	
209	Efficacy and safety of chloroquine and hydroxychloroquine for treatment of COVID-19 patients-a systematic review and meta-analysis of randomized controlled trials. <b>2021</b> , 11, 93-107	9
208	Implementation of platform trials in the COVID-19 pandemic: A rapid review. <b>2021</b> , 112, 106625	2
207	Negacionismo religioso: Bolsonaro e lideranças evangélicas na pandemia Covid-19. <b>2021</b> , 41, 49-74	1
206	Repurposed pharmacological agents for the potential treatment of COVID-19: a literature review. <b>2021</b> , 22, 304	0
205	Treatment of SARS-CoV-2 (COVID-19): A safety perspective. <b>2021</b> , 10, 1-32	0
204	Many Trials of Hydroxychloroquine for SARS-CoV-2 Were Redundant and Potentially Unethical: An Analysis of the NIH Clinical Trials Registry. <b>2021</b> ,	0
203	Pre-exposure prophylaxis with hydroxychloroquine for COVID-19: a double-blind, placebo-controlled randomized clinical trial. <b>2021</b> , 22, 808	4
202	Coronavirus Disease (COVID-19) Control between Drug Repurposing and Vaccination: A Comprehensive Overview. <b>2021</b> , 9,	9
201	Screening of Severe Acute Respiratory Syndrome Coronavirus 2 RNA-Dependent RNA Polymerase Inhibitors Using Computational Approach. <b>2021</b> ,	4
200	A Narrative Review of Existing Options for COVID-19-Specific Treatments. <b>2021</b> , 2021, 8554192	
199	Directly and Simultaneously Expressing Absolute and Relative Treatment Effects in Medical Data Models and Applications. <b>2021</b> , 23,	2
198	Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV. <b>2021</b> , 16, 1341-1370	9
197	Heterologous Vaccination for Preparing COVID-19 Pandemic. <b>2021</b> , 96, 450-454	
196	What is shaping the coronavirus pandemic in Africa?. <b>2020</b> , 9, 374	
195	Fundamentals of genomic epidemiology, lessons learned from the coronavirus disease 2019 (COVID-19) pandemic, and new directions. <b>2021</b> , 1,	2

194	COVID-19 associated cardiac disease: Is there a role of neutrophil extracellular traps in pathogenesis?. <b>2021</b> , 8, 275-290	
193	Translational Modeling of Chloroquine and Hydroxychloroquine Dosimetry in Human Airways for Treating Viral Respiratory Infections.. <b>2022</b> , 39, 57	0
192	In Silico Screening of Potential Phytocompounds from Several Herbs against SARS-CoV-2 Indian Delta Variant B.1.617.2 to Inhibit the Spike Glycoprotein Trimer. <b>2022</b> , 12, 665	1
191	Acute and subacute oral toxicity of artemisinin-hydroxychloroquine sulfate tablets in rats.. <b>2022</b> , 129, 105114	2
190	Lettere. <b>2020</b> , 39, 420-423	1
189	It is time to consider an anti-inflammatory therapy based on the pathophysiology of COVID-19 infection during the right time window?. <b>2020</b> , 17, 546-550	0
188	Male infertility: A scoping review of prevalence, causes and treatments. <b>2021</b> , 10, 195	0
187	COVID-19 Health Information on Google: A QUEST Cross-Sectional Quality and Readability Analysis.. <b>2022</b> ,	0
186	Use of hydroxychloroquine to prevent SARS-CoV-2 infection and treat mild COVID-19: a systematic review and meta-analysis. <b>2021</b> , 47, e20210236	0
185	Therapeutic Interventions Targeting Innate Immune Receptors: A Balancing Act. <b>2021</b> ,	4
184	Plasma therapy: a passive resistance against the deadliest. <b>2021</b> , 1-10	2
183	Evaluation of SARS-CoV-2 entry, inflammation and new therapeutics in human lung tissue cells.. <b>2022</b> , 18, e1010171	3
182	Technical procedures and REDCap tools for internet-based clinical trials.. <b>2022</b> , 106660	0
181	Hospitalization costs for COVID-19 in Ethiopia: Empirical data and analysis from Addis Ababa's largest dedicated treatment center.. <i>PLoS ONE</i> , <b>2022</b> , 17, e0260930	3.7 0
180	Clinical pharmacology: Current innovations and future challenges.. <b>2021</b> ,	0
179	High-cited favorable studies for COVID-19 treatments ineffective in large trials.	
178	COVID-19: les thérapeutiques. <b>2022</b> , 1, 13-13	
177	Understanding the activating mechanism of the immune system against COVID-19 by Traditional Indian Medicine: Network pharmacology approach.. <b>2022</b> , 129, 275-379	1

176	Hydroxychloroquine pre-exposure prophylaxis provides no protection against COVID-19 among health care workers: a cross-sectional study in a tertiary care hospital in North India.. <b>2022,</b>	1
175	LC-MS/MS Method for Determination of Hydroxychloroquine and Metabolites: Application in a Pharmacokinetic Study.. <b>2022,</b> 2022, 6058445	0
174	SARS-CoV-2 and the Host Cell: A Tale of Interactions. <b>2022,</b> 1,	3
173	Outpatient healthcare and clinical trials in the care pathway: Organisational and regulatory aspects and tools.. <b>2022,</b>	
172	Bromhexine Hydrochloride Prophylaxis of COVID-19 for Medical Personnel: A Randomized Open-Label Study.. <b>2022,</b> 2022, 4693121	5
171	Calcium Signals during SARS-CoV-2 Infection: Assessing the Potential of Emerging Therapies.. <b>2022,</b> 11,	6
170	Hydroxychloroquine/Chloroquine for the Treatment of Hospitalized Patients with COVID-19: An Individual Participant Data Meta-Analysis.. <b>2022,</b>	1
169	Air-Liquid-Interface Differentiated Human Nose Epithelium: A Robust Primary Tissue Culture Model of SARS-CoV-2 Infection.. <b>2022,</b> 23,	1
168	Hydroxychloroquine for COVID-19: Variation in Regional Political Preferences Predicted New Prescriptions after President Trump's Endorsement.. <b>2022,</b>	0
167	Hydroxychloroquine/Chloroquine in COVID-19 With Focus on Hospitalized Patients [A Systematic Review.	0
166	« Médecine de ville et essai clinique dans le parcours de soins : aspects organisationnels, réglementaires, outils ». <b>2022,</b> 77, 25-25	
165	Vascular endotheliitis associated with infections: its pathogenetic role and therapeutic implication.. <b>2022,</b> 197, 114909	1
164	Safety and Tolerability of Hydroxychloroquine in healthcare workers and first responders for the prevention of COVID-19: WHIP COVID-19 Study.. <b>2021,</b>	0
163	Drugs used during the COVID-19 first wave in Vitoria-Gasteiz (Spain) and their presence in the environment.. <b>2022,</b> 820, 153122	0
162	Metalloproteinase-dependent and TMPRSS2-independent cell surface entry pathway of SARS-CoV-2 requires the furin-cleavage site and the S2 domain of spike protein.	1
161	Therapeutic Options for Coronavirus Disease 2019 (COVID-19): Where Are We Now?. <b>2021,</b> 23, 28	2
160	Identification and Development of Therapeutics for COVID-19. <b>2021,</b>	
159	Antiviral cyclic peptides targeting the main protease of SARS-CoV-2.. <b>2022,</b> 13, 3826-3836	2

158	Reimagining diaspora diplomacy during the COVID-19 crisis in India.. <b>2022</b> ,	0
157	Hydroxychloroquine pre-exposure prophylaxis for COVID-19 among healthcare workers: Initial experience from India.. <b>2022</b> , 11, 1140-1145	
156	Acute management of COVID-19 in the emergency department: An evidence-based review.. <b>2022</b> , 11, 424-433	0
155	A comprehensive review of adverse events to drugs used in COVID-19 patients: Recent clinical evidence.. <b>2022</b> , e13763	1
154	Severe Infections Due to Respiratory Viruses.. <b>2022</b> , 43, 60-74	0
153	Rationale and Design of the COVID-19 Outpatient Prevention Evaluation (COPE - Coalition V) Randomized Clinical Trial: Hydroxychloroquine vs. Placebo in Non-Hospitalized Patients.. <b>2022</b> , 118, 378-387	1
152	Autophagy-Inflammation Interplay During Infection: Balancing Pathogen Clearance and Host Inflammation.. <b>2022</b> , 13, 832750	1
151	First and second wave of coronavirus-19 disease: A comparative study in patients hospitalized in an ICU of a third-level university hospital.. <b>2021</b> , 46, 166-166	0
150	Ribavirin for treating Lassa fever: A systematic review of pre-clinical studies and implications for human dosing.. <b>2022</b> , 16, e0010289	1
149	COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety.. <b>2022</b> ,	16
148	Organoid Models of SARS-CoV-2 Infection: What Have We Learned about COVID-19?. <b>2022</b> , 1, 2-27	2
147	Maoto, a traditional herbal medicine, for post-exposure prophylaxis for Japanese healthcare workers exposed to COVID-19: A single center study.. <b>2022</b> ,	1
146	Can anti-parasitic drugs help control COVID-19?. <b>2022</b> ,	1
145	Post-COVID-19 syndrome. SARS-CoV-2 RNA detection in plasma, stool, and urine in patients with persistent symptoms after COVID-19.. <b>2022</b> , 22, 211	5
144	Efficacy and Safety of Ivermectin and Hydroxychloroquine in Patients with Severe COVID-19: A Randomized Controlled Trial.. <b>2022</b> , 14, 160-168	3
143	The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication and Decreases Viral Titers and Disease Progression in Syrian Hamsters.. <i>MBio</i> , <b>2022</b> , e0370521	7.8 1
142	Current challenges in different approaches to control COVID-19: a comprehensive review.. <b>2022</b> , 46, 47	0
141	High-cited favorable studies for COVID-19 treatments ineffective in large trials.. <b>2022</b> ,	1



140	Comorbidities and clinical complications associated with SARS-CoV-2 infection: an overview.. <b>2022</b> , 1		0
139	Understanding on the possible routes for SARS CoV-2 invasion via ACE2 in the host linked with multiple organs damage.. <b>2022</b> , 99, 105254		2
138	Liushen Capsules, a promising clinical candidate for COVID-19, alleviates SARS-CoV-2-induced pulmonary in vivo and inhibits the proliferation of the variant virus strains in vitro.. <b>2022</b> , 17, 40		0
137	Serious Cardiovascular Adverse Events Associated with Hydroxychloroquine/Chloroquine Alone or with Azithromycin in Patients with COVID-19: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS).. <b>2022</b> , 1		4
136	Hyperinflammation in COVID-19 and suicide etiopathogenesis: Hypothesis for a nefarious collision?. <b>2022</b> , 104606		0
135	Clinical update on COVID-19 for the emergency and critical care clinician: Medical management.. <b>2022</b> , 56, 158-170		2
134	Hydroxychloroquine versus placebo in the treatment of non-hospitalised patients with COVID-19 (COPE - Coalition V): A double-blind, multicentre, randomised, controlled trial.. <b>2022</b> , 11, 100243		0
133	Pre-exposure Prophylaxis With Various Doses of Hydroxychloroquine Among Healthcare Personnel With High-Risk Exposure to COVID-19: A Randomized Controlled Trial.. <i>Cureus</i> , <b>2021</b> , 13, e20572	1.2	2
132	Gastrointestinal and hepatic side effects of potential treatment for COVID-19 and vaccination in patients with chronic liver diseases.. <b>2021</b> , 13, 1850-1874		1
131	Drug repurposing and other strategies for rapid coronavirus antiviral development: lessons from the early stage of the COVID-19 pandemic. <b>2021</b> , 39-68		
130	Real-world response of COVID-19 patients in Mexico.		
129	Implementation of a fully remote randomized clinical trial with cardiac monitoring. <b>2021</b> , 1,		0
128	A computational biology approach for the identification of potential SARS-CoV-2 main protease inhibitors from natural essential oil compounds.. <i>F1000Research</i> , 10, 1313	3.6	1
127	Safety and efficacy of hydroxychloroquine for treatment of non-severe COVID-19 among adults in Uganda: a randomized open label phase II clinical trial. <b>2021</b> , 21, 1218		0
126	ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up. <b>2021</b> ,		3
125	A Randomized Controlled Trial of Hydroxychloroquine as Prophylaxis for COVID-19 among Health Care Providers. <b>2021</b> , 14, 600-604		0
124	COVID-19 in Children: Update on Diagnosis and Management.. <b>2021</b> , 42, 737-746		
123	Comparison between Dexamethasone and Methylprednisolone Therapy in Patients with COVID-19 Pneumonia Admitted to Non-Intensive Medical Units.. <b>2021</b> , 10,		1

- 122 Antirheumatic Drugs against COVID-19 from the Perspective of Rheumatologists.. **2021**, 14, 2
- 121 Hydroxychloroquine as pre-exposure prophylaxis against COVID-19 infection among healthcare workers: a prospective cohort study. **2021**,
- 120 Patho-Physiology of Aging and Immune-Senescence: Possible Correlates With Comorbidity and Mortality in Middle-Aged and Old COVID-19 Patients. **2021**, 2, 3
- 119 Clinical characteristics and outcomes of COVID-19 in kidney transplant recipients. **2021**, 13, 339-355
- 118 COVID-19: The question of genetic diversity and therapeutic intervention approaches.. **2021**, 44, e20200452 ○
- 117 Virus Entry Inhibitors: Past, Present, and Future.. **2022**, 1366, 1-13
- 116 Assessment of porphyrogenicity of drugs and chemicals in selected hepatic cell culture models through a fluorescence-based screening assay.. **2022**, 10, e00951 ○
- 115 Global Gene Expression and Docking Profiling of COVID-19 Infection.. **2022**, 13, 870836 ○
- 114 Design, Synthesis, and Development of 4-[(7-Chloroquinoline-4-yl)amino]phenol as a Potential SARS-CoV-2 Mpro Inhibitor. **2022**, 7, ○
- 113 Can We Really Trust the Findings of the COVID-19 Research? Quality Assessment of Randomized Controlled Trials Published on COVID-19.
- 112 Data\_Sheet\_1.docx. **2020**,
- 111 Data\_Sheet\_1.pdf. **2020**,
- 110 Image\_1.TIF. **2020**,
- 109 Table\_1.xlsx. **2020**,
- 108 Table\_2.xlsx. **2020**,
- 107 DataSheet\_1.pdf. **2020**,
- 106 DataSheet\_2.pdf. **2020**,
- 105 DataSheet\_1.pdf. **2020**,

104	Safety considerations of chloroquine in the treatment of patients with diabetes and COVID-19.. <b>2022</b> , 109954		0
103	Medication use during COVID-19. <b>2021</b> , 67, 171-179		2
102	Médicaments utilisés durant la COVID-19. <b>2021</b> , 67, e69-e78		
101	Safety profile of hydroxychloroquine used off-label for the treatment of patients with COVID-19: A descriptive study based on EudraVigilance data.. <b>2022</b> ,		0
100	Opportunities and counterintuitive challenges for decentralized clinical trials to broaden participant inclusion.. <b>2022</b> , 5, 58		1
99	Antimicrobials in COVID-19: strategies for treating a COVID-19 pandemic.. <b>2022</b> ,		0
98	Efficacy of add-on Ayurveda and Yoga intervention in health care workers of tertiary care hospital during COVID-19: Randomized controlled trial. <b>2022</b> , 101601		
97	Hydroxychloroquine for COVID19: The curtains close on a comedy of errors.. <b>2022</b> , 11, 100268		1
96	Rash morphology as a predictor of COVID-19 severity: A systematic review of the cutaneous manifestations of COVID-19.		0
95	Hydroxychloroquine and Mortality in SARS-Cov-2 Infection; The HOPE- Covid-19 Registry.. <b>2022</b> , 20,		
94	Safety of Short-Term Treatments with Oral Chloroquine and Hydroxychloroquine in Patients with and without COVID-19: A Systematic Review. <b>2022</b> , 15, 634		1
93	Efficacy of COVID-19 treatments among geriatric patients: a systematic review. <b>2022</b> , 9, 204993612210956		0
92	Hydroxychloroquine plus personal protective equipment versus personal protective equipment alone for the prevention of laboratory-confirmed COVID-19 infections among healthcare workers: a multicentre, parallel-group randomised controlled trial from India. <i>BMJ Open</i> , <b>2022</b> , 12, e059540	3	1
91	Management of Acute Respiratory Distress Syndrome in COVID-19 Patients. <b>2022</b> , 73, 5-14		
90	Outcomes of 2111 COVID-19 Hospitalized Patients Treated with Hydroxychloroquine/Azithromycin and Other Regimens in Marseille, France, 2020: A Monocentric Retrospective Analysis. Volume 18, 603-617		0
89	SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19. <b>2022</b> , 2022,		1
88	Biological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences. <b>2022</b> , 10, 919		2
87	Ivermectin for Treatment of Mild-to-Moderate COVID-19 in the Outpatient Setting: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial.		0

86	Infections in lung transplanted patients: A review. <i>Pulmonology</i> , <b>2022</b> ,	3.7	
85	Changes in dispensing of medicines proposed for re-purposing in the first year of the COVID-19 pandemic in Australia. <i>PLoS ONE</i> , <b>2022</b> , 17, e0269482	3.7	1
84	A computational biology approach for the identification of potential SARS-CoV-2 main protease inhibitors from natural essential oil compounds.. <i>F1000Research</i> , 10, 1313	3.6	0
83	Changes in laboratory value improvement and mortality rates over the course of the pandemic: an international retrospective cohort study of hospitalised patients infected with SARS-CoV-2. <i>BMJ Open</i> , <b>2022</b> , 12, e057725	3	0
82	Metalloproteinase-Dependent and TMPRSS2-Independent Cell Surface Entry Pathway of SARS-CoV-2 Requires the Furin Cleavage Site and the S2 Domain of Spike Protein. <i>MBio</i> ,	7.8	2
81	Longitudinal Cohort Study of Verbatim-Reported Postural Instability Symptoms as Outcomes for Online Parkinson Disease Trials. <i>Journal of Parkinson Disease</i> , <b>2022</b> , 1-10	5.3	
80	Prophylactic use of hydroxychloroquine (HCQS) in COVID-19: A questionnaire-based study in health care professionals. <i>Annals of African Medicine</i> , <b>2022</b> , 21, 113	1.7	
79	Hydroxychloroquine/chloroquine prophylaxis among health-care workers: Was it really preventive? Evidence from a multicentric cross-sectional study. <i>Indian Journal of Community Medicine</i> , <b>2022</b> , 47, 202	0.8	
78	Antiparasitic Drugs against SARS-CoV-2: A Comprehensive Literature Survey. <i>Microorganisms</i> , <b>2022</b> , 10, 1284	4.9	1
77	Study on Hydroxychloroquine Sulfate Being Given to the Admitted COVID -19 Positive Patients at Institute of JLNMCH, Bhagalpur, Bihar, India. <i>Cureus</i> , <b>2022</b> ,	1.2	
76	Mortality and risk factors for COVID-19 in hemodialysis patients: A systematic review and meta-analysis. <i>Science Progress</i> , <b>2022</b> , 105, 003685042211108	1.1	0
75	Leveraging Real-World Data in COVID-19 Response. <i>Statistics in Biopharmaceutical Research</i> , 1-33	1.2	
74	Inhaled Fluticasone for Outpatient Treatment of Covid-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial.		
73	Additively manufactured electrodes for the electrochemical detection of hydroxychloroquine. <i>Talanta</i> , <b>2022</b> , 250, 123727	6.2	0
72	Trends in COVID-19 patient characteristics in a large electronic health record database in the United States: A cohort study. <b>2022</b> , 17, e0271501		1
71	MIS-C and co-infection with <i>P. vivax</i> and <i>P. falciparum</i> in a child: a clinical conundrum. <b>2022</b> , 48,		0
70	Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19. <b>2022</b> , 387, 599-610		13
69	Demarcating Patriotic Science on Digital Platforms: Covid-19, Chloroquine and the Institutionalisation of Ignorance in Brazil. 1-25		2

68	Using time-weighted average change from baseline of SARS-CoV-2 viral load to assess impact of hydroxychloroquine as postexposure prophylaxis and early treatment for COVID-19.	
67	Authorization of COVID-19 clinical trials: lessons from 2 years of experience of a national competent authority. 13,	
66	Modeling SARS-CoV-2 and influenza infections and antiviral treatments in human lung epithelial tissue equivalents. <b>2022</b> , 5,	0
65	Eye-Related COVID-19: A Bibliometric Analysis of the Scientific Production Indexed in Scopus. <b>2022</b> , 19, 9927	0
64	Polygenic autoimmune disease risk alleles impacting B cell tolerance act in concert across shared molecular networks in mouse and in humans. 13,	0
63	Extracorporeal membrane oxygenation for COVID -19: An evolving experience through multiple waves.	1
62	Incidence of Stroke in Randomized Trials of COVID-19 Therapeutics: A Systematic Review and Meta-Analysis.	1
61	Systematic review and meta-analysis of randomized trials of hydroxychloroquine for the prevention of COVID-19.	3
60	Targeted therapy in Coronavirus disease 2019 (COVID-19): Implication from cell and gene therapy to immunotherapy and vaccine. <b>2022</b> , 111, 109161	2
59	Pre-hospital Management of COVID-19: Looking for a Future Perspective. <b>2022</b> , 395-419	0
58	Evolution of Approaches to Therapeutic Prevention and Treatment of the New Coronavirus Infection. <b>2022</b> , 92, 430-436	0
57	Pela Ciência, contra os cientistas? Negacionismo e as disputas em torno das políticas de saúde durante a pandemia. <b>2022</b> , 24, 98-138	0
56	Acute and subacute oral toxicity of artemisinin-hydroxychloroquine sulfate tablets in beagle dogs. 1-9	0
55	COVID-19 and Pulmonary Diseases. <b>2022</b> , 230-262	0
54	Development of SARS-CoV-2 infection in patients with rheumatic conditions on hydroxychloroquine monotherapy vs. patients without rheumatic conditions: a retrospective, propensity-matched cohort study. <b>2022</b> ,	0
53	Identification of Suitable Drug Combinations for Treating COVID-19 Using a Novel Machine Learning Approach: The RAIN Method. <b>2022</b> , 12, 1456	0
52	Putative Therapeutic Impact of Inflammasome Inhibitors against COVID-19-Induced ARDS. <b>2022</b> , 29,	0
51	Hydroxychloroquine/chloroquine for the treatment of hospitalized patients with COVID-19: An individual participant data meta-analysis. <b>2022</b> , 17, e0273526	0

50	Characteristics of SARS-CoV-2 Infection in an Actively Monitored Cohort of Patients with Lupus Nephritis. <b>2022</b> , 10, 2423	0
49	Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19.	6
48	Care for adults with COVID -19: living guidelines from the National COVID -19 Clinical Evidence Taskforce. <b>2022</b> , 217, 368-378	1
47	Herbo-mineral formulation, Divya-Swasari-Vati averts SARS-CoV-2 pseudovirus entry into human alveolar epithelial cells by interfering with spike protein-ACE 2 interaction and IL-6/TNF- $\alpha$ /NF- $\kappa$ B signaling. 13,	0
46	Effect of Aducanumab Approval on Willingness to Participate in Preclinical Alzheimer's Disease Trials. <b>2022</b> , 1-10	0
45	Fluvoxamine for Outpatient Treatment of COVID-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial.	0
44	Cellular Landscaping of COVID-19 and Gynaecological Cancers: An Infrequent Correlation. <b>2022</b> , 2022, 1-15	0
43	The failure of drug repurposing for COVID-19 as an effect of excessive hypothesis testing and weak mechanistic evidence. <b>2022</b> , 44,	0
42	Treatment and case fatality rate of COVID-19 in Africa. <b>2022</b> , 13,	0
41	Distribution of age, sex, race, and ethnicity in COVID-19 clinical drug trials in the United States: A review. <b>2022</b> , 123, 106997	0
40	A Review Pertaining to SARS-CoV-2 and Autoimmune Diseases: What Is the Connection?. <b>2022</b> , 12, 1918	0
39	Hydroxychloroquine for treatment of COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials. <b>2022</b> , 20,	1
38	Lung-on-chip microdevices to foster pulmonary drug discovery.	0
37	Heparin Inhibits SARS-CoV-2 Replication in Human Nasal Epithelial Cells. <b>2022</b> , 14, 2620	0
36	Biologic Functions of Hydroxychloroquine in Disease: From COVID-19 to Cancer. <b>2022</b> , 14, 2551	0
35	Hypertension related toxicity of chloroquine explains its failure against COVID-19: Based on rat model. 13,	0
34	Antidepressant drug prescription and incidence of COVID-19: a retrospective cohort study.	0
33	The Use and Safety Risk of Repurposed Drugs for COVID-19 patients: Lessons Learned Utilizing the Food and Drug Administration's Adverse Event Reporting System.	0

32	Hospital-Based Quasi-Experimental Study on Hydroxychloroquine Pre-Exposure Prophylaxis for COVID-19 in Healthcare Providers with Its Potential Side-Effects. <b>2022</b> , 12, 2047	0
31	Elective Colorectal Surgery Service Provision during SARS-CoV-2 Pandemic. <b>2022</b> , 42, 327-334	0
30	Misinterpretation of statistical nonsignificance as a sign of potential bias: Hydroxychloroquine as a case study. 1-20	0
29	Pharmacological Effects and Clinical Prospects of Cepharanthine. <b>2022</b> , 27, 8933	0
28	Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19.	3
27	The Myth of Hydroxychloroquine (HCQ) as post-exposure prophylaxis (PEP) for the prevention of COVID-19 is far from reality. <b>2023</b> , 13,	0
26	Hydroxychloroquine for treatment of non-hospitalized adults with COVID -19: A meta-analysis of individual participant data of randomized trials.	0
25	Electrochemical sensor based on a ZnO-doped graphitized carbon for the electrocatalytic detection of the antibiotic hydroxychloroquine. Application: tap water and human urine.	0
24	Anthracyclines inhibit SARS-CoV-2 infection.	0
23	Clinical Research: A Review of Study Designs, Hypotheses, Errors, Sampling Types, Ethics, and Informed Consent. <b>2023</b> ,	0
22	Drug Repurposing in COVID-19 and Cancer: How Far Have We Come?. <b>2023</b> , 519-528	0
21	The NCSBN 2023 Environmental Scan: Nursing at a CrossroadsAn Opportunity for Action. <b>2023</b> , 13, S1-S48	0
20	Efficacy of hydroxychloroquine in pre-exposure severe acute respiratory syndrome coronavirus 2 prophylaxis among high-risk healthcare workers: A multicenter study. <b>2023</b> , 12, 3	0
19	Antimalarial drugs. <b>2023</b> , 363-396	0
18	Antimalarials and macrolides: a review of off-label pharmacotherapies during the first wave of the SARS-CoV-2 pandemic. 59,	0
17	The development of COVID-19 treatment. 14,	2
16	Effects of hydroxychloroquine on atrial electrophysiology in in silico wild-type and PITX2+/- atrial cardiomyocytes.	0
15	Prophylactic treatment with oral azithromycin in cancer patients during the COVID-19 pandemic (OnCoVID): a randomized, single-blinded, placebo-controlled phase 2 trial. <b>2023</b> , 18,	0

- 14 Novel Tetrahydroisoquinoline-Based Heterocyclic Compounds Efficiently Inhibit SARS-CoV-2 Infection In Vitro. **2023**, 15, 502
- 13 Clinical and electrocardiographic outcomes evaluated by telemedicine of outpatients with clinical suspicion of COVID-19 treated with chloroquine compounds in Brazil
- 12 Harnessing the Power of Venomous Animal-Derived Toxins against COVID-19. **2023**, 15, 159
- 11 Hydroxychloroquine to prevent SARS-CoV-2 infection among healthcare workers: early termination of a phase 3, randomised, open-label, controlled clinical trial. **2023**, 16,
- 10 Discovery of therapeutic targets of quercetin for endometrial carcinoma patients infected with COVID-19 through network pharmacology. 13,
- 9 Mechanistic insight into the protective and pathogenic immune-responses against SARS-CoV-2. **2023**, 156, 111-126
- 8 Preface to the second edition. **2023**, xxi-xxvii
- 7 How have mathematical models contributed to understanding the transmission and control of SARS-CoV-2 in healthcare settings? A systematic search and review.
- 6 Inclusion in clinical research: cross-sectional study assessing potential barriers to informed consent in randomized controlled trials published in top general and internal medical journals.
- 5 Diagnosis, treatment protocols, and outcomes of liver transplant recipients infected with COVID-19. 11, 2140-2159
- 4 Early Treatment with Hydroxychloroquine and Azithromycin: A Real-Life Monocentric Retrospective Cohort Study of 30,423 COVID-19 Patients.
- 3 Current Strategies to Combat COVID-19. **2023**, 361-374
- 2 Exploring the Link Between Malaria and COVID-19. **2023**, 311-338
- 1 Insight into the liver dysfunction in COVID-19 patients: Molecular mechanisms and possible therapeutic strategies. 29, 2064-2077